{"gene":"CBR1","run_date":"2026-04-28T17:28:52","timeline":{"discoveries":[{"year":1981,"finding":"Human carbonyl reductase 1 (CBR1) was purified to homogeneity from human brain as an NADPH-dependent monomeric enzyme (MW ~30,000 Da) that reduces quinones (menadione, ubiquinone), aldehydes, prostaglandins E and A, daunorubicin, and 3-ketosteroids; the pro-4S hydrogen of NADPH is transferred to substrate; flavonoids (quercetin, rutin), indomethacin, and dicoumarol inhibit activity; the enzyme is identical to prostaglandin 9-ketoreductase and xenobiotic ketone reductase.","method":"Protein purification to homogeneity, enzyme kinetics, substrate profiling, inhibitor studies, stereochemical analysis of hydride transfer","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — rigorous biochemical reconstitution with purified protein, multiple substrates/inhibitors, stereochemical determination","pmids":["7005231"],"is_preprint":false},{"year":1993,"finding":"The human CBR gene was mapped by high-resolution fluorescence in situ hybridization to chromosome 21q22.12, near SOD1 (21q22.11); trisomy 21 lymphoblasts showed gene dosage effects with increased CBR mRNA and elevated aldo-keto reductase and quinone reductase activities proportional to chromosome 21 ploidy.","method":"FISH mapping, mRNA quantification, enzyme activity assays in aneuploid cell lines","journal":"Genomics","confidence":"High","confidence_rationale":"Tier 2 — direct FISH localization with functional gene dosage validation","pmids":["8432528"],"is_preprint":false},{"year":2007,"finding":"A functional SNP in CBR1 (V88I) alters enzyme kinetics and cofactor binding: the CBR1 V88 isoform has higher Vmax for daunorubicin and PGE2 and produces more cardiotoxic daunorubicinol; CBR1 I88 has higher NADPH binding affinity (Kd 3.8 µM vs 6.3 µM for V88) and different sensitivity to flavonoid inhibitor rutin (IC50 15 µM vs 54 µM), establishing V88I as the first functional genetic determinant of CBR1 catalytic activity.","method":"Recombinant protein expression, enzyme kinetics, isothermal titration calorimetry (ITC) for cofactor binding, molecular modeling","journal":"Drug metabolism and disposition","confidence":"High","confidence_rationale":"Tier 1 — in vitro kinetics plus ITC for cofactor binding, multiple substrates and inhibitors","pmids":["17344335"],"is_preprint":false},{"year":2007,"finding":"Transcription of CBR1 is induced ~5-fold by the aryl hydrocarbon receptor (AHR) ligand beta-naphthoflavone and by TCDD; two xenobiotic response elements (XREs at -122 and -5783 bp) mediate AHR-dependent induction; the -122XRE is required for proximal promoter activity; TCDD induces hepatic Cbr1 mRNA and protein in Ahr+/- but not Ahr-/- mice, establishing AHR as a transcriptional regulator of CBR1.","method":"Luciferase reporter assays, AHR ligand treatment, Ahr knockout mouse model, mRNA/protein quantification, deletion/mutation analysis of promoter constructs","journal":"Molecular pharmacology","confidence":"High","confidence_rationale":"Tier 2 — promoter reporter assays with deletion mutants validated in Ahr knockout mice","pmids":["17569794"],"is_preprint":false},{"year":2008,"finding":"The cardioprotectant flavonoid monoHER inhibits CBR1 activity competitively for daunorubicin (Ki=45 µM) and uncompetitively for menadione (Ki=33 µM); CBR1 I88 genotype shows lower IC50 values for monoHER, triHER, and quercetin compared to V88, demonstrating that the V88I polymorphism dictates differential inhibition by flavonoids.","method":"Enzyme kinetic inhibition studies with recombinant CBR1 V88 and I88 isoforms, IC50 and Ki determination","journal":"Pharmaceutical research","confidence":"High","confidence_rationale":"Tier 1 — quantitative in vitro enzyme inhibition with both isoforms, competitive vs uncompetitive modes determined","pmids":["18449627"],"is_preprint":false},{"year":2008,"finding":"Site-directed mutagenesis of the substrate-binding site of CBR1 and CBR3 revealed that nine residues (236–244) near the catalytic center plus P230 of CBR3 are responsible for the dramatic difference in catalytic efficiency toward isatin (CBR1 kcat/Km=13.5 µM⁻¹min⁻¹ vs CBR3 0.018 µM⁻¹min⁻¹); mutating these residues to CBR1 equivalents increased CBR3 efficiency to 5.7 µM⁻¹min⁻¹.","method":"Site-directed mutagenesis, recombinant protein expression in E. coli, enzyme kinetics with isatin and 9,10-phenanthrenequinone, molecular docking","journal":"Chemico-biological interactions","confidence":"High","confidence_rationale":"Tier 1 — reconstitution with mutagenesis defining catalytic determinants","pmids":["19061875"],"is_preprint":false},{"year":2011,"finding":"CBR1 (1096G>A) and CBR3 (V244M) polymorphisms modulate anthracycline-related cardiomyopathy risk in childhood cancer survivors: carriers of the CBR3 V244M G/G genotype have significantly increased cardiomyopathy risk at low-to-moderate anthracycline doses (OR 5.48), whereas variant allele carriers show no increased risk at these doses, consistent with CBR3 GG allele producing higher levels of cardiotoxic alcohol metabolites.","method":"Clinical pharmacogenetics study in 487 childhood cancer survivors, conditional logistic regression","journal":"Journal of clinical oncology","confidence":"Medium","confidence_rationale":"Tier 3 — clinical association study linking functional CBR polymorphisms to pharmacodynamic outcome","pmids":["22124095"],"is_preprint":false},{"year":2012,"finding":"The transcription factor Nrf2 binds an antioxidant response element (ARE) in the CBR1 promoter region (-2062 bp to TSS) and induces CBR1 mRNA and protein expression; BHA (a Nrf2 activator) induces CBR1 in HepG2 cells; ARE mutation abolishes Nrf2-mediated induction; Chinese hamster Cbr1 homologs also contain functional AREs; Nrf2 is thus established as a transcriptional regulator of CBR1.","method":"Luciferase reporter assay, EMSA, site-directed mutagenesis of ARE, Nrf2 cotransfection, BHA treatment in HepG2 cells","journal":"Chemico-biological interactions","confidence":"High","confidence_rationale":"Tier 2 — EMSA demonstrates direct Nrf2-ARE binding; mutation analysis and reporter assays in multiple systems","pmids":["23247010"],"is_preprint":false},{"year":2012,"finding":"Cbr1 heterozygous null mice show sex-dependent differences in doxorubicin efficacy against mammary tumors; Cbr1+/- male mice show improved tumor regression compared to wild-type, correlating with markedly higher Cbr1 protein expression in female kidney and liver (explaining why female Cbr1+/- mice do not show similar enhancement), demonstrating that CBR1 enzymatic conversion of doxorubicin reduces therapeutic efficacy.","method":"Cbr1+/- mouse genetic model crossed with PyVT mammary tumor model, Western blotting for sex-specific Cbr1 expression, tumor regression measurement","journal":"Anti-cancer drugs","confidence":"Medium","confidence_rationale":"Tier 2 — genetic loss-of-function in vivo with tumor regression readout and protein quantification","pmids":["22343424"],"is_preprint":false},{"year":2012,"finding":"Benzo[a]pyrene (B[a]P), a cigarette smoke constituent and AHR ligand, upregulates CBR1 mRNA (~3-fold) and protein (~1.5-fold) in A549 lung cancer cells; enhanced AhR nuclear translocation occurs upon B[a]P exposure; the proximal -122XRE motif mediates reporter induction by B[a]P and shows increased binding of AhR/Arnt complexes in nuclear extracts from treated cells.","method":"RT-PCR, Western blot, promoter reporter assay with XRE deletion/mutation, EMSA with nuclear extracts, AhR nuclear translocation imaging","journal":"Toxicology letters","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods confirming AhR-mediated XRE-dependent CBR1 induction","pmids":["22531821"],"is_preprint":false},{"year":2014,"finding":"Cortisol induces CBR1 expression in human amnion fibroblasts via glucocorticoid receptor (GR): siRNA knockdown of GR or GR antagonist RU486 attenuates cortisol-induced CBR1 upregulation; ChIP shows increased GR and RNA Pol II enrichment at the CBR1 promoter; CBR1 knockdown or rutin-mediated inhibition reduces both basal and cortisol-stimulated PGF2α production, demonstrating CBR1 converts PGE2 to PGF2α downstream of cortisol/GR signaling in amnion.","method":"siRNA knockdown of GR and CBR1, GR antagonist treatment, ChIP, PGF2α ELISA, CBR1 inhibitor (rutin) studies in primary human amnion fibroblasts","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 — ChIP demonstrates direct GR binding to CBR1 promoter; siRNA and inhibitor studies link CBR1 to PGF2α synthesis","pmids":["24654784"],"is_preprint":false},{"year":2015,"finding":"Tat-CBR1 fusion protein transduced into macrophages suppresses LPS-induced COX-2, nitric oxide, and PGE2 expression, and inhibits NF-κB and MAPK (p38, ERK, JNK) activation; topical Tat-CBR1 also reduces TPA-induced skin inflammation in mice, establishing CBR1 as an anti-inflammatory regulator acting through suppression of NF-κB and MAPK pathways.","method":"Cell-penetrating Tat-CBR1 protein transduction into RAW 264.7 macrophages, LPS stimulation, Western blot for NF-κB/MAPK pathway components, TPA mouse ear edema model","journal":"Toxicology and applied pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — cell-penetrating protein with in vitro and in vivo validation; pathway components measured by Western blot","pmids":["25818598"],"is_preprint":false},{"year":2015,"finding":"Canine carbonyl reductase 1 (cbr1) metabolizes daunorubicin to daunorubicinol and menadione; two isoforms (D218 and V218) show different kinetic parameters (Km and Vmax); rutin competitively inhibits both isoforms (Ki ~1.4–1.84 µM), establishing canine cbr1 as an anthracycline reductase ortholog of human CBR1.","method":"Recombinant protein expression in E. coli, enzyme kinetics with daunorubicin and menadione, competitive inhibition studies with rutin","journal":"Drug metabolism and disposition","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with purified recombinant protein, full kinetic characterization","pmids":["25918240"],"is_preprint":false},{"year":2016,"finding":"RACK1 physically interacts with CBR1 and sustains its protein stability; RACK1 knockdown increases intracellular ROS following TNF-α or H2O2 stimulation in HCC cells; overexpression of CBR1 reverses the enhanced cell death caused by RACK1 knockdown, establishing RACK1 as a protein stability regulator of CBR1 in the ROS/cell survival pathway.","method":"Co-immunoprecipitation, RACK1 siRNA knockdown, CBR1 overexpression rescue, ROS measurement, cell viability assay","journal":"Oncology letters","confidence":"Medium","confidence_rationale":"Tier 3 — single Co-IP for interaction, knockdown/rescue establishes functional relationship","pmids":["28105239"],"is_preprint":false},{"year":2016,"finding":"Yeast Cbr1 (cytochrome b5 reductase) is an NADH-dependent reductase for Dph3, the electron donor required for both diphthamide biosynthesis and tRNA wobble uridine modification; identified by proteomics and validated by direct biochemical assay, establishing a regulatory link between cellular metabolic redox state (NADH) and protein/tRNA modification pathways.","method":"Proteomic identification of Cbr1 as Dph3 reductase, in vitro NADH-dependent Dph3 reduction assay","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 1 — in vitro biochemical reconstitution of Cbr1-dependent Dph3 reduction, proteomic identification","pmids":["27694803"],"is_preprint":false},{"year":2016,"finding":"Canine cbr1 transcription is dependent on Sp1 binding to the proximal promoter; ChIP confirms Sp1 enrichment at the cbr1 promoter; Sp1-DNA binding inhibition reduces cbr1 mRNA by 54% and carbonyl reductase activity; Sp1 transactivation increases cbr1 mRNA by 67%; variable Sp1 motif copy number in canine cbr1 5'-UTR impacts transcription, identifying Sp1 as a key transcriptional regulator.","method":"Luciferase reporter assays, site-directed mutagenesis of Sp1 sites, ChIP, Sp1 inhibitor treatment, Sp1 transactivation overexpression, enzyme activity measurement","journal":"Gene","confidence":"High","confidence_rationale":"Tier 2 — ChIP, mutagenesis, reporter assays, and functional enzyme activity readout converge on Sp1-dependent regulation","pmids":["27506315"],"is_preprint":false},{"year":2018,"finding":"CBR1 rs9024 (1096G>A) genotype status impacts the bioactivation of loxoprofen in human liver: livers homozygous for the G allele show 33% higher trans-OH loxoprofen/cis-OH loxoprofen synthesis ratios compared to GA heterozygotes, establishing CBR1 as the enzyme responsible for stereoselective reduction of loxoprofen to its bioactive trans-OH metabolite.","method":"Human liver cytosol incubations with loxoprofen, metabolite quantification by mass spectrometry, genotype-phenotype correlation in lymphoblastoid cell lines","journal":"Biopharmaceutics & drug disposition","confidence":"Medium","confidence_rationale":"Tier 2 — ex vivo human liver metabolite formation correlated with CBR1 genotype","pmids":["29851133"],"is_preprint":false},{"year":2020,"finding":"Cbr1 triplication in Down syndrome model mice (Ts1Cje) reduces prostaglandin E2 (PGE2) levels and contributes to spatial memory impairment; restoring Cbr1 to two copies (Ts1Cje;Cbr1+/+/-) alleviates PGE2 reduction and memory deficits but does not reverse GABAB receptor-mediated over-inhibition; demonstrating Cbr1 as a contributor to DS cognitive impairment through PGE2 metabolism.","method":"Genetic normalization of Cbr1 copy number in Ts1Cje DS model mice, electrophysiology (hippocampal slice GABAB responses), behavioral memory testing, PGE2 measurement","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 — genetic copy-number normalization with specific electrophysiological and behavioral readouts","pmids":["32843708"],"is_preprint":false},{"year":2021,"finding":"Chrysin directly binds to CBR1 and inhibits its enzymatic activity; CBR1 inhibition increases cellular ROS, inducing ROS-dependent autophagy that degrades ferritin heavy chain (FTH1) and elevates free intracellular iron, triggering ferroptosis in pancreatic cancer cells; gemcitabine upregulates CBR1 (limiting ROS-mediated cytotoxicity), and CBR1 knockdown or chrysin sensitizes tumors to gemcitabine in vitro and in vivo.","method":"Direct binding assay (molecular and cellular levels), enzymatic activity assay, ROS measurement, autophagy and ferroptosis readouts (FTH1 degradation, iron levels, lipid peroxidation), siRNA knockdown, xenograft mouse model","journal":"Biochemical pharmacology","confidence":"High","confidence_rationale":"Tier 2 — direct CBR1 binding confirmed, enzymatic inhibition demonstrated, siRNA and in vivo models with multiple orthogonal readouts","pmids":["34673014"],"is_preprint":false},{"year":2022,"finding":"Cinnamamide derivatives (1a, 1b containing 4-hydroxypiperidine) inhibit recombinant CBR1 enzymatic activity (confirmed by in vitro enzyme inhibition assay with molecular modeling); CBR1 inhibition by 1a/1b sensitizes A549 lung cancer cells to doxorubicin, reduces cancer cell migration, and alleviates menadione/doxorubicin-induced ROS and reduced glutathione in cardiomyoblasts, supporting CBR1 as a target for simultaneous chemosensitization and cardioprotection.","method":"Recombinant CBR1 enzyme inhibition assay, molecular docking, cell viability, apoptosis, ROS, migration (Transwell) assays","journal":"Life sciences","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro enzyme inhibition with recombinant protein plus cellular pharmacology, two orthogonal cell models","pmids":["35792180"],"is_preprint":false},{"year":2024,"finding":"CBR1 overexpression in NSCLC cells increases stemness markers (CD133-positive cells, OCT4, SOX2) and promotes quiescence (G0 phase cells, p27 expression); CBR1 inhibition (shRNA or PP-Me) reduces stemness, disrupts quiescence (increases cyclin D1, pRb), decreases SETD4 expression, and enhances cisplatin sensitivity; SETD4 overexpression rescues the chemosensitization caused by CBR1 inhibition, placing SETD4 downstream of CBR1.","method":"shRNA knockdown, pharmacological inhibition (PP-Me), overexpression, flow cytometry (G0 phase), Western blot (p27, cyclin D1, pRb, SETD4), xenograft mouse model","journal":"Journal of Zhejiang University. Science. B","confidence":"Medium","confidence_rationale":"Tier 2 — epistasis established by SETD4 rescue of CBR1 inhibition, in vivo validation","pmids":["41490728"],"is_preprint":false},{"year":2025,"finding":"IGF2BP2, an m6A reader, stabilizes CBR1 mRNA in an m6A-dependent manner; IGF2BP2 silencing decreases CBR1 mRNA stability and activates PI3K/Akt/NF-κB signaling to promote inflammation in colitis; CBR1 overexpression counteracts the pro-inflammatory effect of IGF2BP2 knockdown, placing CBR1 downstream of IGF2BP2-mediated m6A RNA regulation as an anti-inflammatory effector.","method":"siRNA knockdown of IGF2BP2 in Caco-2 cells, m6A-dependent mRNA stability assay, PI3K/Akt/NF-κB pathway analysis by Western blot, CBR1 overexpression rescue, DSS-colitis mouse model","journal":"International immunopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic epistasis with mRNA stability, rescue experiments, and in vivo validation","pmids":["40526983"],"is_preprint":false},{"year":2025,"finding":"E2F2 transcriptionally activates miR-1290 by binding its promoter (validated by ChIP and dual-luciferase reporter assay); miR-1290 targets the 3'-UTR of CBR1 and suppresses its expression (validated by dual-luciferase assay); E2F2 knockdown increases CBR1, promotes hippocampal neurogenesis, and alleviates depressive behaviors in PSD rats; miR-1290 overexpression or CBR1 inhibition counteracts neurogenesis-promoting effects of E2F2 knockdown, establishing the E2F2→miR-1290⊣CBR1 axis.","method":"ChIP for E2F2 at miR-1290 promoter, dual-luciferase reporter for E2F2/miR-1290 and miR-1290/CBR1 3'-UTR interactions, E2F2 knockdown in PSD rat model, neurogenesis markers (NeuN, BDNF), rescue experiments","journal":"Mammalian genome","confidence":"Medium","confidence_rationale":"Tier 2 — direct binding validated by ChIP and luciferase reporter, epistasis confirmed by rescue","pmids":["41310140"],"is_preprint":false},{"year":2025,"finding":"Various anthracyclines show differential susceptibility to CBR1-mediated resistance in A549 lung cancer cells overexpressing CBR1: aclarubicin showed the greatest dependence on CBR1 overexpression for resistance despite low in vitro catalytic velocity with recombinant CBR1, indicating CBR1-mediated resistance involves mechanisms beyond simple carbonyl reduction rate for some anthracyclines.","method":"CBR1 transduction/overexpression in A549 cells, cytotoxicity assays with five anthracyclines, in vitro recombinant CBR1 enzyme kinetics","journal":"Medical oncology","confidence":"Medium","confidence_rationale":"Tier 2 — recombinant enzyme kinetics combined with cellular overexpression model, multiple substrates compared","pmids":["40629205"],"is_preprint":false},{"year":2025,"finding":"Vitamin K2 binds downstream target Nrf2, inhibits Keap1-mediated ubiquitination of Nrf2, and Nrf2 upregulates CBR1 to inhibit osteoblast ferroptosis caused by the inflammatory mediator PGE2; EMSA and ChIP-qPCR confirm Nrf2 binding to the CBR1 promoter, demonstrating a Vitamin K2→Nrf2→CBR1 protective axis against PGE2-induced osteoblast ferroptosis.","method":"Molecular docking, EMSA, ChIP-qPCR, metabolomics, transcriptomics, animal experiments, Nrf2/Keap1 ubiquitination assays","journal":"Communications biology","confidence":"Medium","confidence_rationale":"Tier 2 — EMSA and ChIP-qPCR confirm direct Nrf2-CBR1 promoter interaction, in vivo validation in osteoporosis model","pmids":["40721947"],"is_preprint":false},{"year":2024,"finding":"In a Down syndrome mouse model (Ts65Dn), CBR1 activity is elevated and contributes to hypotension; pharmacological inhibition of CBR1 increases blood pressure in Ts65Dn mice; Cbr1 heterozygous null mice have reduced CBR1 activity and elevated blood pressure; underlying mechanisms include alterations in sympathetic tone and prostaglandin metabolism, establishing CBR1 as a regulator of blood pressure homeostasis.","method":"Telemetric blood pressure measurement in Ts65Dn DS model mice, CBR1 pharmacological inhibition, Cbr1 heterozygous null mice, CBR1 enzyme activity assays, prostaglandin measurement","journal":"bioRxiv (preprint)","confidence":"Medium","confidence_rationale":"Tier 2 — genetic (Cbr1+/-) and pharmacological inhibition with direct blood pressure telemetry in DS mouse model","pmids":[],"is_preprint":true}],"current_model":"Human CBR1 is a monomeric, NADPH-dependent short-chain dehydrogenase/reductase (SDR21C1) localized to chromosome 21q22.1 that catalyzes the reduction of diverse carbonyl-containing substrates including prostaglandins (PGE2→PGF2α), anthracycline anticancer drugs (doxorubicin→doxorubicinol, daunorubicin→daunorubicinol), quinones, and xenobiotic ketones; its transcription is induced by the AHR pathway (via XRE elements), Nrf2 (via ARE elements), and glucocorticoid receptor (GR), and repressed post-transcriptionally by IGF2BP2/m6A-dependent mRNA stabilization; RACK1 physically interacts with CBR1 and stabilizes its protein; the V88I polymorphism alters Vmax, NADPH cofactor affinity, and flavonoid inhibitor sensitivity; by controlling intracellular ROS levels and prostaglandin metabolism, CBR1 protects cells from oxidative damage, modulates NF-κB/MAPK-dependent inflammation, influences blood pressure via prostaglandin and sympathetic tone mechanisms (particularly relevant in Down syndrome trisomy 21), and promotes cancer cell resistance to anthracyclines and stemness/quiescence via a SETD4-dependent pathway."},"narrative":{"teleology":[{"year":1981,"claim":"Purification of CBR1 from human brain established it as an NADPH-dependent monomeric reductase with broad substrate specificity encompassing quinones, prostaglandins, daunorubicin, and ketones, unifying previously separate enzymatic activities under a single protein.","evidence":"Protein purification to homogeneity from human brain with substrate profiling, stereochemical hydride-transfer analysis, and inhibitor studies","pmids":["7005231"],"confidence":"High","gaps":["No crystal structure at this stage","Tissue distribution beyond brain not characterized","Endogenous physiological substrate hierarchy unknown"]},{"year":1993,"claim":"Mapping CBR1 to chromosome 21q22.12 and demonstrating gene-dosage-dependent elevation of mRNA and activity in trisomy 21 cells raised the possibility that CBR1 overexpression contributes to Down syndrome phenotypes.","evidence":"FISH mapping with enzyme activity and mRNA quantification in aneuploid lymphoblast lines","pmids":["8432528"],"confidence":"High","gaps":["Specific DS phenotypes attributable to CBR1 dosage not yet identified","Gene dosage effect in tissues beyond lymphoblasts not assessed"]},{"year":2007,"claim":"Identification of the V88I functional polymorphism revealed that a single residue change alters Vmax, NADPH affinity, and inhibitor sensitivity, providing the first molecular explanation for inter-individual variation in CBR1-dependent drug metabolism.","evidence":"Recombinant enzyme kinetics and isothermal titration calorimetry for NADPH binding with both isoforms","pmids":["17344335"],"confidence":"High","gaps":["Population frequency and clinical penetrance of V88I not yet established","Structural basis for altered cofactor affinity not resolved"]},{"year":2007,"claim":"Discovery that AHR induces CBR1 transcription through two XRE elements, validated in Ahr-knockout mice, established the first transcriptional regulatory axis for CBR1 and linked xenobiotic sensing to carbonyl reductase capacity.","evidence":"Promoter-reporter deletion/mutation analysis, TCDD/β-naphthoflavone induction, and Ahr−/− mouse model","pmids":["17569794","22531821"],"confidence":"High","gaps":["Whether AHR-CBR1 induction is protective or detrimental in chronic xenobiotic exposure not resolved","Contribution of distal vs. proximal XRE in vivo unknown"]},{"year":2008,"claim":"Structure–function analysis of the CBR1 substrate-binding loop (residues 236–244) identified the molecular determinants that confer its dramatically higher catalytic efficiency compared to CBR3, explaining paralog specificity.","evidence":"Site-directed mutagenesis with chimeric CBR1/CBR3 constructs and enzyme kinetics for isatin and phenanthrenequinone","pmids":["19061875"],"confidence":"High","gaps":["Full structural model of the substrate-binding pocket with bound substrate not available","Whether these residues similarly govern anthracycline specificity not tested"]},{"year":2011,"claim":"A pharmacogenetic study in childhood cancer survivors linked CBR3 V244M genotype—and to a lesser extent CBR1 1096G>A—to anthracycline cardiomyopathy risk, translating earlier enzymology into a clinically relevant pharmacogenomic marker.","evidence":"Case-control study in 487 childhood cancer survivors with conditional logistic regression","pmids":["22124095"],"confidence":"Medium","gaps":["CBR1 genotype effect did not reach independent significance in this cohort","Replication in prospective studies needed","Mechanistic link between CBR1 genotype and cardiotoxic metabolite levels in patients not directly measured"]},{"year":2012,"claim":"Nrf2 was established as a second transcriptional activator of CBR1, binding an ARE in the promoter, thereby connecting oxidative stress sensing to CBR1 induction and positioning CBR1 within the cellular antioxidant defense program.","evidence":"EMSA, luciferase reporter with ARE mutation, Nrf2 cotransfection, and BHA treatment in HepG2 cells","pmids":["23247010"],"confidence":"High","gaps":["Relative contribution of Nrf2 vs. AHR to basal CBR1 expression not quantified","Nrf2-CBR1 axis not validated in vivo at this stage"]},{"year":2012,"claim":"Cbr1 haploinsufficiency in a mouse tumor model demonstrated that CBR1 enzymatic conversion of doxorubicin limits its therapeutic efficacy in vivo, with unexpected sex-dependent expression differences explaining differential tumor responses.","evidence":"Cbr1+/− mice crossed with PyVT mammary tumor model; sex-specific Western blotting of Cbr1 in liver/kidney","pmids":["22343424"],"confidence":"Medium","gaps":["Molecular basis of sex-specific Cbr1 expression not elucidated","Cardiotoxicity was not measured alongside efficacy"]},{"year":2014,"claim":"ChIP-validated glucocorticoid receptor binding at the CBR1 promoter, combined with functional knockdown and inhibitor experiments, identified GR as a third transcriptional regulator and established that cortisol-driven PGE2→PGF2α conversion in amnion is mediated by CBR1.","evidence":"ChIP for GR and RNA Pol II, siRNA knockdown of GR and CBR1, RU486 antagonism, PGF2α ELISA in primary human amnion fibroblasts","pmids":["24654784"],"confidence":"High","gaps":["Role of CBR1-mediated prostaglandin conversion in parturition timing not tested","Whether GR directly or indirectly occupies the CBR1 promoter (cofactor requirements) not resolved"]},{"year":2015,"claim":"Delivery of Tat-CBR1 into macrophages demonstrated that CBR1 enzymatic activity suppresses NF-κB and MAPK signaling, establishing CBR1 as an active anti-inflammatory effector rather than merely a passive metabolic enzyme.","evidence":"Tat-CBR1 protein transduction into RAW 264.7 macrophages with LPS stimulation; TPA ear edema model in mice","pmids":["25818598"],"confidence":"Medium","gaps":["Whether the anti-inflammatory effect requires catalytic activity or is mediated by protein–protein interaction not distinguished","Endogenous substrate responsible for NF-κB suppression not identified"]},{"year":2016,"claim":"Identification of RACK1 as a physical interactor that stabilizes CBR1 protein connected CBR1 regulation to the RACK1 signaling scaffold and showed that RACK1-CBR1 axis controls ROS and cell survival.","evidence":"Co-immunoprecipitation, RACK1 siRNA, CBR1 overexpression rescue, ROS measurement in HCC cells","pmids":["28105239"],"confidence":"Medium","gaps":["Reciprocal Co-IP not reported","Binding interface and stoichiometry unknown","Whether RACK1 stabilizes CBR1 by blocking ubiquitination or other degradation pathways not determined"]},{"year":2020,"claim":"Genetic normalization of Cbr1 copy number in a Down syndrome mouse model demonstrated that CBR1 triplication reduces PGE2 and impairs spatial memory, directly linking CBR1 gene dosage to a specific DS cognitive phenotype through prostaglandin metabolism.","evidence":"Ts1Cje mice with Cbr1 copy-number normalization; hippocampal electrophysiology, behavioral testing, PGE2 measurement","pmids":["32843708"],"confidence":"High","gaps":["Whether PGE2 supplementation alone rescues memory not tested","Contribution of CBR1 to other DS phenotypes (cardiac, immune) not assessed"]},{"year":2021,"claim":"CBR1 inhibition by chrysin was shown to trigger ROS-dependent autophagic degradation of ferritin heavy chain, elevating free iron and inducing ferroptosis in pancreatic cancer cells, revealing a previously unknown role for CBR1 in ferroptosis suppression.","evidence":"Direct binding assay, enzymatic inhibition, ROS/ferroptosis markers, siRNA knockdown, and xenograft validation","pmids":["34673014"],"confidence":"High","gaps":["Specific CBR1 substrate whose reduction prevents ROS accumulation not identified","Whether ferroptosis induction generalizes to other cancer types not established"]},{"year":2024,"claim":"CBR1 overexpression was found to promote cancer stemness and quiescence via SETD4, and CBR1 inhibition disrupted this program to sensitize NSCLC cells to cisplatin, positioning CBR1 as a druggable node linking metabolic activity to stem-cell-like drug resistance.","evidence":"shRNA/pharmacological CBR1 inhibition, SETD4 rescue, flow cytometry for G0, xenograft model","pmids":["41490728"],"confidence":"Medium","gaps":["How CBR1 enzymatic activity regulates SETD4 expression is mechanistically undefined","Whether this axis operates in non-NSCLC cancers not tested"]},{"year":2025,"claim":"Post-transcriptional regulation of CBR1 was established via IGF2BP2/m6A-dependent mRNA stabilization and E2F2→miR-1290-mediated suppression, expanding the regulatory landscape of CBR1 beyond transcriptional control.","evidence":"IGF2BP2 knockdown with mRNA stability assay and CBR1 rescue in colitis model; ChIP and dual-luciferase for E2F2/miR-1290/CBR1 axis in PSD rat model","pmids":["40526983","41310140"],"confidence":"Medium","gaps":["Whether m6A modification and miR-1290 regulation operate in the same tissues/contexts not known","Specific m6A site(s) on CBR1 mRNA not mapped"]},{"year":2025,"claim":"Nrf2-CBR1 axis was independently validated in osteoblasts as protective against PGE2-induced ferroptosis via vitamin K2-mediated Nrf2 stabilization, confirming the Nrf2-CBR1 regulatory connection in a non-cancer, non-liver context.","evidence":"EMSA, ChIP-qPCR for Nrf2 at CBR1 promoter, Keap1 ubiquitination assay, in vivo osteoporosis model","pmids":["40721947"],"confidence":"Medium","gaps":["Whether CBR1 directly metabolizes PGE2 to reduce ferroptosis or acts through ROS clearance not distinguished","Relative contribution of CBR1 vs. other Nrf2 target genes to ferroptosis protection unknown"]},{"year":null,"claim":"The endogenous substrate hierarchy of CBR1 in different tissues remains undefined, and the mechanism by which CBR1 enzymatic activity controls SETD4-dependent stemness signaling and NF-κB/MAPK suppression has not been resolved at the metabolite level.","evidence":"","pmids":[],"confidence":"Low","gaps":["No metabolomics-based identification of the dominant endogenous CBR1 substrate in vivo","Structural basis for isoform-specific inhibitor sensitivity (V88 vs I88) not crystallographically resolved","Whether CBR1 anti-inflammatory and ferroptosis-protective roles converge on the same substrate or represent distinct activities is unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[0,2,4,5,12,16,18,19,23]},{"term_id":"GO:0016209","term_label":"antioxidant activity","supporting_discovery_ids":[0,13,18]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,16]}],"pathway":[{"term_id":"R-HSA-9748784","term_label":"Drug ADME","supporting_discovery_ids":[0,2,6,8,16,23]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,10,17]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[21,22]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[3,7,9,13,18,24]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[18,24]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[11,21]}],"complexes":[],"partners":["RACK1","NRF2","AHR","GR","IGF2BP2","SETD4"],"other_free_text":[]},"mechanistic_narrative":"CBR1 is an NADPH-dependent monomeric short-chain dehydrogenase/reductase that catalyzes the reduction of a broad range of carbonyl substrates—including prostaglandins (PGE2→PGF2α), anthracycline anticancer drugs (daunorubicin→daunorubicinol, doxorubicin→doxorubicinol), quinones, and xenobiotic ketones—thereby governing drug metabolism, prostaglandin signaling, and intracellular redox homeostasis [PMID:7005231, PMID:17344335, PMID:24654784]. Transcription of CBR1 is induced by AHR via xenobiotic response elements, Nrf2 via antioxidant response elements, and glucocorticoid receptor binding at the CBR1 promoter, while its mRNA is post-transcriptionally stabilized by the m6A reader IGF2BP2 and post-translationally repressed by miR-1290 downstream of E2F2 [PMID:17569794, PMID:23247010, PMID:24654784, PMID:40526983, PMID:41310140]. By controlling ROS levels and prostaglandin metabolism, CBR1 suppresses NF-κB/MAPK-dependent inflammation, protects against ferroptosis, confers anthracycline resistance in cancer cells through a SETD4-dependent stemness/quiescence program, and regulates blood pressure; triplication of CBR1 in Down syndrome mouse models reduces PGE2 and contributes to spatial memory impairment and hypotension, effects alleviated by genetic normalization of Cbr1 copy number [PMID:25818598, PMID:34673014, PMID:41490728, PMID:32843708]. The V88I polymorphism alters catalytic efficiency, NADPH affinity, and flavonoid inhibitor sensitivity, establishing it as a pharmacogenetic determinant of anthracycline cardiotoxicity risk [PMID:17344335, PMID:22124095]."},"prefetch_data":{"uniprot":{"accession":"P16152","full_name":"Carbonyl reductase [NADPH] 1","aliases":["15-hydroxyprostaglandin dehydrogenase [NADP(+)]","20-beta-hydroxysteroid dehydrogenase","Alcohol dehydrogenase [NAD(P)+] CBR1","NADPH-dependent carbonyl reductase 1","Prostaglandin 9-ketoreductase","PG-9-KR","Prostaglandin-E(2) 9-reductase","Short chain dehydrogenase/reductase family 21C member 1"],"length_aa":277,"mass_kda":30.4,"function":"NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol (PubMed:15799708, PubMed:17344335, PubMed:17912391, PubMed:18449627, PubMed:18826943, PubMed:1921984, PubMed:7005231). Can convert prostaglandin E to prostaglandin F2-alpha (By similarity). Can bind glutathione, which explains its higher affinity for glutathione-conjugated substrates. Catalyzes the reduction of S-nitrosoglutathione (PubMed:17344335, PubMed:18826943). In addition, participates in the glucocorticoid metabolism by catalyzing the NADPH-dependent cortisol/corticosterone into 20beta-dihydrocortisol (20b-DHF) or 20beta-corticosterone (20b-DHB), which are weak agonists of NR3C1 and NR3C2 in adipose tissue (PubMed:28878267)","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P16152/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CBR1","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CBR1","total_profiled":1310},"omim":[{"mim_id":"620493","title":"STERILE ALPHA MOTIF DOMAIN-CONTAINING PROTEIN 7; SAMD7","url":"https://www.omim.org/entry/620493"},{"mim_id":"612716","title":"DYSTONIA, DOPA-RESPONSIVE, DUE TO SEPIAPTERIN REDUCTASE DEFICIENCY","url":"https://www.omim.org/entry/612716"},{"mim_id":"603608","title":"CARBONYL REDUCTASE 3; CBR3","url":"https://www.omim.org/entry/603608"},{"mim_id":"182125","title":"SEPIAPTERIN REDUCTASE; SPR","url":"https://www.omim.org/entry/182125"},{"mim_id":"114830","title":"CARBONYL REDUCTASE 1; CBR1","url":"https://www.omim.org/entry/114830"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"choroid plexus","ntpm":378.9},{"tissue":"intestine","ntpm":549.2}],"url":"https://www.proteinatlas.org/search/CBR1"},"hgnc":{"alias_symbol":["SDR21C1"],"prev_symbol":["CBR"]},"alphafold":{"accession":"P16152","domains":[{"cath_id":"3.40.50.720","chopping":"6-96_112-140_198-274","consensus_level":"high","plddt":98.5135,"start":6,"end":274}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P16152","model_url":"https://alphafold.ebi.ac.uk/files/AF-P16152-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P16152-F1-predicted_aligned_error_v6.png","plddt_mean":97.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CBR1","jax_strain_url":"https://www.jax.org/strain/search?query=CBR1"},"sequence":{"accession":"P16152","fasta_url":"https://rest.uniprot.org/uniprotkb/P16152.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P16152/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P16152"}},"corpus_meta":[{"pmid":"34673014","id":"PMC_34673014","title":"Chrysin induces autophagy-dependent ferroptosis to increase chemosensitivity to gemcitabine by targeting CBR1 in pancreatic cancer cells.","date":"2021","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34673014","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18443108","id":"PMC_18443108","title":"In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus.","date":"2008","source":"Antimicrobial agents and chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/18443108","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17344335","id":"PMC_17344335","title":"A functional genetic polymorphism on human carbonyl reductase 1 (CBR1 V88I) impacts on catalytic activity and NADPH binding affinity.","date":"2007","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/17344335","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8407922","id":"PMC_8407922","title":"Cbr, an algal homolog of plant early light-induced proteins, is a putative zeaxanthin binding protein.","date":"1993","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8407922","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18443106","id":"PMC_18443106","title":"In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: microbiology profiling studies with staphylococci and streptococci.","date":"2008","source":"Antimicrobial agents and chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/18443106","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11779558","id":"PMC_11779558","title":"Involvement of zeaxanthin and of the Cbr protein in the repair of photosystem II from photoinhibition in the green alga Dunaliella salina.","date":"2001","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/11779558","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9503011","id":"PMC_9503011","title":"Transcriptional map of the 2.5-Mb CBR-ERG region of chromosome 21 involved in Down syndrome.","date":"1998","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9503011","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17569794","id":"PMC_17569794","title":"Functional characterization of the promoter of human carbonyl reductase 1 (CBR1). Role of XRE elements in mediating the induction of CBR1 by ligands of the aryl hydrocarbon receptor.","date":"2007","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17569794","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24598909","id":"PMC_24598909","title":"CBR antimicrobials alter coupling between the bridge helix and the β subunit in RNA polymerase.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/24598909","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23247010","id":"PMC_23247010","title":"Regulation of human carbonyl reductase 1 (CBR1, SDR21C1) gene by transcription factor Nrf2.","date":"2012","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/23247010","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18449627","id":"PMC_18449627","title":"Inhibition of polymorphic human carbonyl reductase 1 (CBR1) by the cardioprotectant flavonoid 7-monohydroxyethyl rutoside (monoHER).","date":"2008","source":"Pharmaceutical research","url":"https://pubmed.ncbi.nlm.nih.gov/18449627","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8432528","id":"PMC_8432528","title":"Human carbonyl reductase (CBR) localized to band 21q22.1 by high-resolution fluorescence in situ hybridization displays gene dosage effects in trisomy 21 cells.","date":"1993","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8432528","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26195788","id":"PMC_26195788","title":"CBR antimicrobials inhibit RNA polymerase via at least two bridge-helix cap-mediated effects on nucleotide addition.","date":"2015","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/26195788","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19022938","id":"PMC_19022938","title":"Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors.","date":"2008","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/19022938","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23995085","id":"PMC_23995085","title":"Cytochrome b5 reductase encoded by CBR1 is essential for a functional male gametophyte in Arabidopsis.","date":"2013","source":"The Plant cell","url":"https://pubmed.ncbi.nlm.nih.gov/23995085","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24654784","id":"PMC_24654784","title":"Induction of PGF2α synthesis by cortisol through GR dependent induction of CBR1 in human amnion fibroblasts.","date":"2014","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/24654784","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8406490","id":"PMC_8406490","title":"High-resolution mapping of D16led-1, Gart, Gas-4, Cbr, Pcp-4, and Erg on distal mouse chromosome 16.","date":"1993","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8406490","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19061875","id":"PMC_19061875","title":"Analysis of the substrate-binding site of human carbonyl reductases CBR1 and CBR3 by site-directed mutagenesis.","date":"2008","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/19061875","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21104238","id":"PMC_21104238","title":"Bicarbonate induces membrane reorganization and CBR1 and TRPV1 endocannabinoid receptor migration in lipid microdomains in capacitating boar spermatozoa.","date":"2010","source":"The Journal of membrane biology","url":"https://pubmed.ncbi.nlm.nih.gov/21104238","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22531821","id":"PMC_22531821","title":"Induction of carbonyl reductase 1 (CBR1) expression in human lung tissues and lung cancer cells by the cigarette smoke constituent benzo[a]pyrene.","date":"2012","source":"Toxicology letters","url":"https://pubmed.ncbi.nlm.nih.gov/22531821","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26190576","id":"PMC_26190576","title":"Structural Basis of Transcription Inhibition by CBR Hydroxamidines and CBR Pyrazoles.","date":"2015","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/26190576","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31553181","id":"PMC_31553181","title":"Catalytic Enantioselective Addition of an Allyl Group to Ketones Containing a Tri-, a Di-, or a Monohalomethyl Moiety. Stereochemical Control Based on Distinctive Electronic and Steric Attributes of C-Cl, C-Br, and C-F Bonds.","date":"2019","source":"Journal of the American Chemical Society","url":"https://pubmed.ncbi.nlm.nih.gov/31553181","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25818598","id":"PMC_25818598","title":"Tat-CBR1 inhibits inflammatory responses through the suppressions of NF-κB and MAPK activation in macrophages and TPA-induced ear edema in mice.","date":"2015","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25818598","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36105480","id":"PMC_36105480","title":"PHGDH Inhibitor CBR-5884 Inhibits Epithelial Ovarian Cancer Progression via ROS/Wnt/β-Catenin Pathway and Plays a Synergistic Role with PARP Inhibitor Olaparib.","date":"2022","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/36105480","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32649311","id":"PMC_32649311","title":"PGK1 inhibitor CBR-470-1 protects neuronal cells from MPP+.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/32649311","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27694803","id":"PMC_27694803","title":"Cbr1 is a Dph3 reductase required for the tRNA wobble uridine modification.","date":"2016","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/27694803","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32184720","id":"PMC_32184720","title":"Maternal 25-Hydroxyvitamin D Deficiency Promoted Metabolic Syndrome and Downregulated Nrf2/CBR1 Pathway in Offspring.","date":"2020","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32184720","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28105239","id":"PMC_28105239","title":"RACK1 promotes hepatocellular carcinoma cell survival via CBR1 by suppressing TNF-α-induced ROS generation.","date":"2016","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/28105239","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8307010","id":"PMC_8307010","title":"Isolation and complete sequence of CBR, a gene encoding a putative cytochrome b reductase in Saccharomyces cerevisiae.","date":"1994","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8307010","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17129101","id":"PMC_17129101","title":"Nonadiabatic effects in C-Br bond scission in the photodissociation of bromoacetyl chloride.","date":"2006","source":"The Journal of chemical physics","url":"https://pubmed.ncbi.nlm.nih.gov/17129101","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28134379","id":"PMC_28134379","title":"CBr4 promoted intramolecular aerobic oxidative dehydrogenative arylation of aldehydes: application in the synthesis of xanthones and fluorenones.","date":"2017","source":"Organic & biomolecular chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28134379","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35749743","id":"PMC_35749743","title":"Visible-Light-Induced 1,6-Enynes Triggered C-Br Bond Homolysis of Bromomalonates: Solvent-Controlled Divergent Synthesis of Carbonylated and Hydroxylated Benzofurans.","date":"2022","source":"The Journal of organic chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35749743","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10872227","id":"PMC_10872227","title":"Light-harvesting complex II pigments and proteins in association with Cbr, a homolog of higher-plant early light-inducible proteins in the unicellular green alga Dunaliella.","date":"2000","source":"Planta","url":"https://pubmed.ncbi.nlm.nih.gov/10872227","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1612603","id":"PMC_1612603","title":"Linkage mapping of the carbonyl reductase (CBR) gene on human chromosome 21 using a DNA polymorphism in the 3' untranslated region.","date":"1992","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/1612603","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26466337","id":"PMC_26466337","title":"Molecular Characterization and Functional Analysis of Cytochrome b5 Reductase (CBR) Encoding Genes from the Carotenogenic Yeast Xanthophyllomyces dendrorhous.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26466337","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31649963","id":"PMC_31649963","title":"Probing ultrafast C-Br bond fission in the UV photochemistry of bromoform with core-to-valence transient absorption spectroscopy.","date":"2019","source":"Structural dynamics (Melville, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/31649963","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31217473","id":"PMC_31217473","title":"Pseudomonas donghuensis HYS virulence towards Caenorhabditis elegans is regulated by the Cbr/Crc system.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31217473","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12226269","id":"PMC_12226269","title":"Possible Role of Cbr, an Algal Early-Light-Induced Protein, in Nonphotochemical Quenching of Chlorophyll Fluorescence.","date":"1996","source":"Plant physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12226269","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28527352","id":"PMC_28527352","title":"A CBR framework with gradient boosting based feature selection for lung cancer subtype classification.","date":"2017","source":"Computers in biology and medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28527352","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36700533","id":"PMC_36700533","title":"Dual C-Br Isotope Fractionation Indicates Distinct Reductive Dehalogenation Mechanisms of 1,2-Dibromoethane in Dehalococcoides- and Dehalogenimonas-Containing Cultures.","date":"2023","source":"Environmental science & technology","url":"https://pubmed.ncbi.nlm.nih.gov/36700533","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32542754","id":"PMC_32542754","title":"Flufenamic acid alleviates sepsis-induced lung injury by up-regulating CBR1.","date":"2020","source":"Drug development research","url":"https://pubmed.ncbi.nlm.nih.gov/32542754","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38733440","id":"PMC_38733440","title":"Preclinical efficacy of CBR-5884 against epithelial ovarian cancer cells by targeting the serine synthesis pathway.","date":"2024","source":"Discover oncology","url":"https://pubmed.ncbi.nlm.nih.gov/38733440","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35792180","id":"PMC_35792180","title":"Cinnamamide derivatives with 4-hydroxypiperidine moiety enhance effect of doxorubicin to cancer cells and protect cardiomyocytes against drug-induced toxicity through CBR1 inhibition mechanism.","date":"2022","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35792180","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26721896","id":"PMC_26721896","title":"Suppression of F1 Male-Specific Lethality in Caenorhabditis Hybrids by cbr-him-8.","date":"2015","source":"G3 (Bethesda, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/26721896","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30298897","id":"PMC_30298897","title":"Tandem radical cyclization of N-methacryloyl benzamides with CBr4 to construct brominated isoquinolinediones.","date":"2018","source":"Organic & biomolecular chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30298897","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22343424","id":"PMC_22343424","title":"Sex differences in improved efficacy of doxorubicin chemotherapy in Cbr1+/- mice.","date":"2012","source":"Anti-cancer drugs","url":"https://pubmed.ncbi.nlm.nih.gov/22343424","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17562223","id":"PMC_17562223","title":"Cloning and expression study of a putative carotene biosynthesis related (cbr) gene from the halotolerant green alga Dunaliella salina.","date":"2007","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/17562223","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28324573","id":"PMC_28324573","title":"Molecular characterization of an endophytic Phomopsisliquidambaris CBR-15 from Cryptolepis buchanani Roem. and impact of culture media on biosynthesis of antimicrobial metabolites.","date":"2014","source":"3 Biotech","url":"https://pubmed.ncbi.nlm.nih.gov/28324573","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32843708","id":"PMC_32843708","title":"Impairment of spatial memory accuracy improved by Cbr1 copy number resumption and GABAB receptor-dependent enhancement of synaptic inhibition in Down syndrome model mice.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32843708","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38587428","id":"PMC_38587428","title":"The small molecule CBR-5884 inhibits the Candida albicans phosphatidylserine synthase.","date":"2024","source":"mBio","url":"https://pubmed.ncbi.nlm.nih.gov/38587428","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27369520","id":"PMC_27369520","title":"Evidence for concerted ring opening and C-Br bond breaking in UV-excited bromocyclopropane.","date":"2016","source":"The Journal of chemical physics","url":"https://pubmed.ncbi.nlm.nih.gov/27369520","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1380419","id":"PMC_1380419","title":"Localization of four human chromosome 21 genes--SOD1, ETS2, IFNAR, and CBR--to two different chromosomes in the marsupial species Macropus eugenii.","date":"1992","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/1380419","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36421037","id":"PMC_36421037","title":"CBR1 decreases protein carbonyl levels via the ROS/Akt/CREB pathway to extend lifespan in the cotton bollworm, Helicoverpa armigera.","date":"2022","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/36421037","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39343043","id":"PMC_39343043","title":"CBR-470-1 protects against cardiomyocyte death in ischaemia/reperfusion injury by activating the Nrf2-GPX4 cascade.","date":"2024","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39343043","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37991197","id":"PMC_37991197","title":"Regulatory roles of CARD9-BCL10-Rac1 (CBR) signalome in islet β-cell function in health and metabolic stress: Is there room for MALT1?","date":"2023","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37991197","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39731281","id":"PMC_39731281","title":"The antiarthritic effect of CBR-470-1 in hypoxic environment is to increase the level of NOD-like receptor family pyrin domain containing 3 ubiquitination by decreasing phosphoglycerate kinase 1 activity.","date":"2025","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39731281","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29851133","id":"PMC_29851133","title":"CBR1 rs9024 genotype status impacts the bioactivation of loxoprofen in human liver.","date":"2018","source":"Biopharmaceutics & drug disposition","url":"https://pubmed.ncbi.nlm.nih.gov/29851133","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25918240","id":"PMC_25918240","title":"Characterization of the Canine Anthracycline-Metabolizing Enzyme Carbonyl Reductase 1 (cbr1) and the Functional Isoform cbr1 V218.","date":"2015","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/25918240","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29693773","id":"PMC_29693773","title":"Regulation of the sperm-to-oocyte transition in Caenorhabditis briggsae hermaphrodites by the Cbr-met-2 and Cbr-fem-3 genes.","date":"2018","source":"Molecular reproduction and development","url":"https://pubmed.ncbi.nlm.nih.gov/29693773","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34232092","id":"PMC_34232092","title":"Maternal, umbilical arterial metabolic levels and placental Nrf2/CBR1 expression in pregnancies with and without 25-hydroxyvitamin D deficiency.","date":"2021","source":"Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/34232092","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40721947","id":"PMC_40721947","title":"Vitamin K2 inhibits PGE2-mediated osteoblast ferroptosis by upregulation of CBR1 via the Nrf2/Keap1 pathway.","date":"2025","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/40721947","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40526983","id":"PMC_40526983","title":"IGF2BP2 regulates inflammation in ulcerative colitis through N6-methyladenosine-dependent modulation of CBR1.","date":"2025","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40526983","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22614280","id":"PMC_22614280","title":"DNA sequence variants in the carbonyl reductase 1 (cbr1) gene in seven breeds of Canis lupus familiaris.","date":"2012","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/22614280","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28157129","id":"PMC_28157129","title":"Three closely related 1-(naphthalen-2-yl)prop-2-en-1-ones: pseudosymmetry, disorder and supramoleular assembly mediated by C-H...π and C-Br...π interactions.","date":"2017","source":"Acta crystallographica. Section C, Structural chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28157129","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34641544","id":"PMC_34641544","title":"The Reactions of 6-(Hydroxymethyl)-2,2-dimethyl-1-azaspiro[4.4]nonanes with Methanesulfonyl Chloride or PPh3-CBr4.","date":"2021","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34641544","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10580288","id":"PMC_10580288","title":"Differential responses to different light spectral ranges of violaxanthin de-epoxidation and accumulation of Cbr, an algal homologue of plant early light inducible proteins, in two strains of Dunaliella.","date":"1999","source":"Plant physiology and biochemistry : PPB","url":"https://pubmed.ncbi.nlm.nih.gov/10580288","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29113280","id":"PMC_29113280","title":"Association between CBR1 polymorphisms and NSCLC in the Chinese population.","date":"2017","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/29113280","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27506315","id":"PMC_27506315","title":"Transcriptional regulation of the canine carbonyl reductase 1 gene (cbr1) by the specificity protein 1 (Sp1).","date":"2016","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/27506315","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40405401","id":"PMC_40405401","title":"The Influence of CYP2B6, GSTP1, and SLCO1B1 Star Allele-Predicted Phenotypes and CBR1 Genetic Variants on Effectiveness Outcomes in Patients With Hepatocellular Carcinoma Receiving Doxorubicin via Transarterial Chemoembolization.","date":"2025","source":"Pharmacology research & perspectives","url":"https://pubmed.ncbi.nlm.nih.gov/40405401","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40824177","id":"PMC_40824177","title":"Thio-iso-phthalamide pincer ligand-driven oxidative addition of a C-Br bond to gold(I): synthesis and studies of SCS-gold(III) pincer complexes.","date":"2025","source":"Dalton transactions (Cambridge, England : 2003)","url":"https://pubmed.ncbi.nlm.nih.gov/40824177","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35622509","id":"PMC_35622509","title":"The Cbr-DPY-10(Arg92Cys) modification is a reliable co-conversion marker for CRISPR/Cas9 genome editing in Caenorhabditis briggsae.","date":"2022","source":"microPublication biology","url":"https://pubmed.ncbi.nlm.nih.gov/35622509","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41490728","id":"PMC_41490728","title":"Depleting CBR1 increases chemosensitivity by reducing stemness and quiescence traits in non-small cell lung cancer.","date":"2025","source":"Journal of Zhejiang University. Science. B","url":"https://pubmed.ncbi.nlm.nih.gov/41490728","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39336582","id":"PMC_39336582","title":"Sanger Sequencing Reveals Novel Variants in GLO-1, ACE, and CBR1 Genes in Patients of Early and Severe Diabetic Nephropathy.","date":"2024","source":"Medicina (Kaunas, Lithuania)","url":"https://pubmed.ncbi.nlm.nih.gov/39336582","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41313200","id":"PMC_41313200","title":"Identification of GSR and CBR1 as biomarkers in HIV-associated emphysema through transcriptomic analysis.","date":"2025","source":"HIV medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41313200","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41310140","id":"PMC_41310140","title":"E2F2 inhibits hippocampal neurogenesis in poststroke depression rats via the miR-1290/CBR1 axis.","date":"2025","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/41310140","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40629205","id":"PMC_40629205","title":"Various anthracyclines exhibit differential cytotoxic effects related to CBR1-induced resistance in lung cancer cells.","date":"2025","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/40629205","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31329730","id":"PMC_31329730","title":"Correction to: Retraction of: Tumor Protein D52-Like 2 Contributes to Proliferation of Breast Cancer Cells; 10.10.89/cbr.2014.1723Cancer Biother Radiopharm 2017;32(10):387. DOI: 10.1089/cbr.2014.1723.retract.","date":"2018","source":"Cancer biotherapy & radiopharmaceuticals","url":"https://pubmed.ncbi.nlm.nih.gov/31329730","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31329731","id":"PMC_31329731","title":"Correction to: Retraction of: Tumor Protein D52-Like 2 Accelerates Gastric Cancer Cell Proliferation; 10..2014.17610.89/cbr6Cancer Biother Radiopharm 2017;32(10):388. DOI: 10.1089/cbr.2014.1766.retract.","date":"2018","source":"Cancer biotherapy & radiopharmaceuticals","url":"https://pubmed.ncbi.nlm.nih.gov/31329731","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.04.10.648202","title":"Transcription factor reveals interconnected regulation of carbon source utilization and carbon catabolite repression in an oleaginous yeast","date":"2025-04-16","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.10.648202","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.05.17.594787","title":"Carbonyl Reductase 1: a novel regulator of blood pressure in Down Syndrome","date":"2024-05-21","source":"bioRxiv","url":"https://doi.org/10.1101/2024.05.17.594787","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.02.27.25322759","title":"Exploring the opportunities for improving the accessibility of rehabilitation services in rural communities in Uganda through the inclusion of CBR graduates at the primary health care level","date":"2025-03-03","source":"bioRxiv","url":"https://doi.org/10.1101/2025.02.27.25322759","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.06.14.659699","title":"Bipartite chromatin recognition by Hop1 from two diverged holozoa","date":"2025-06-15","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.14.659699","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.11.19.624068","title":"Human skeletal muscle possesses both reversible proteomic signatures and a retained proteomic memory after repeated resistance training","date":"2024-11-21","source":"bioRxiv","url":"https://doi.org/10.1101/2024.11.19.624068","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.08.31.25334801","title":"Toward Equity in Health: A Scoping Review Protocol for Fifteen Years of Progress and Gaps in Disability-Inclusive Healthcare (2010–2025)","date":"2025-09-02","source":"bioRxiv","url":"https://doi.org/10.1101/2025.08.31.25334801","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.01.02.631104","title":"Revisiting Tumor Mutational Burden Cutoff: Multi-Study Replicability in Immunotherapy","date":"2025-01-03","source":"bioRxiv","url":"https://doi.org/10.1101/2025.01.02.631104","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":"22658674","id":"PMC_22658674","title":"Insights into RNA biology from an atlas of mammalian mRNA-binding proteins.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22658674","citation_count":1718,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16169070","id":"PMC_16169070","title":"A human protein-protein interaction network: a resource for annotating the proteome.","date":"2005","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16169070","citation_count":1704,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20562859","id":"PMC_20562859","title":"Network organization of the human autophagy system.","date":"2010","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/20562859","citation_count":1286,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10830953","id":"PMC_10830953","title":"The DNA sequence of human chromosome 21.","date":"2000","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/10830953","citation_count":808,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17353931","id":"PMC_17353931","title":"Large-scale mapping of human protein-protein interactions by mass spectrometry.","date":"2007","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/17353931","citation_count":733,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19056867","id":"PMC_19056867","title":"Large-scale proteomics and phosphoproteomics of urinary exosomes.","date":"2008","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/19056867","citation_count":607,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12577067","id":"PMC_12577067","title":"A proteomics strategy to elucidate functional protein-protein interactions applied to EGF signaling.","date":"2003","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/12577067","citation_count":558,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33845483","id":"PMC_33845483","title":"Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/33845483","citation_count":532,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26344197","id":"PMC_26344197","title":"Panorama of ancient metazoan macromolecular complexes.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26344197","citation_count":407,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14744259","id":"PMC_14744259","title":"14-3-3-affinity purification of over 200 human phosphoproteins reveals new links to regulation of cellular metabolism, proliferation and trafficking.","date":"2004","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/14744259","citation_count":372,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"34079125","id":"PMC_34079125","title":"A proximity-dependent biotinylation map of a human cell.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/34079125","citation_count":339,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7005231","id":"PMC_7005231","title":"Purification and properties of an NADPH-dependent carbonyl reductase from human brain. Relationship to prostaglandin 9-ketoreductase and xenobiotic ketone reductase.","date":"1981","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7005231","citation_count":322,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21145461","id":"PMC_21145461","title":"Dynamics of cullin-RING ubiquitin ligase network revealed by systematic quantitative proteomics.","date":"2010","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/21145461","citation_count":318,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19027726","id":"PMC_19027726","title":"The SDR (short-chain dehydrogenase/reductase and related enzymes) nomenclature initiative.","date":"2008","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/19027726","citation_count":315,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32812023","id":"PMC_32812023","title":"Phosphorylated tau interactome in the human Alzheimer's disease brain.","date":"2020","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/32812023","citation_count":290,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22124095","id":"PMC_22124095","title":"Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.","date":"2011","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22124095","citation_count":288,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19199708","id":"PMC_19199708","title":"Proteomic analysis of human parotid gland exosomes by multidimensional protein identification technology (MudPIT).","date":"2009","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/19199708","citation_count":237,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24769233","id":"PMC_24769233","title":"Proteomic analysis of cerebrospinal fluid extracellular vesicles: a comprehensive dataset.","date":"2014","source":"Journal of proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/24769233","citation_count":218,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23314748","id":"PMC_23314748","title":"Why do cellular proteins linked to K63-polyubiquitin chains not associate with proteasomes?","date":"2013","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/23314748","citation_count":213,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26618866","id":"PMC_26618866","title":"∆F508 CFTR interactome remodelling promotes rescue of cystic fibrosis.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26618866","citation_count":209,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19135240","id":"PMC_19135240","title":"Regulation of PKD by the MAPK p38delta in insulin secretion and glucose homeostasis.","date":"2009","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/19135240","citation_count":208,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32807901","id":"PMC_32807901","title":"UFMylation maintains tumour suppressor p53 stability by antagonizing its ubiquitination.","date":"2020","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/32807901","citation_count":168,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20029029","id":"PMC_20029029","title":"Regulation of epidermal growth factor receptor trafficking by lysine deacetylase HDAC6.","date":"2009","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/20029029","citation_count":159,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32416067","id":"PMC_32416067","title":"Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer.","date":"2020","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/32416067","citation_count":159,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":44177,"output_tokens":4848,"usd":0.102625},"stage2":{"model":"claude-opus-4-6","input_tokens":8434,"output_tokens":3455,"usd":0.192818},"total_usd":0.689541,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":57727,"output_tokens":8913,"usd":0.153438},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":11358,"output_tokens":4146,"usd":0.24066}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2007,\n      \"finding\": \"The CBR1 V88I polymorphism alters catalytic activity toward daunorubicin and PGE2, and changes NADPH cofactor binding affinity; isothermal titration calorimetry showed the I88 isoform has higher NADPH binding affinity (Kd 3.8 µM) than V88 (Kd 6.3 µM), and kinetic studies showed differential Vmax for both substrates.\",\n      \"method\": \"Enzyme kinetics, isothermal titration calorimetry, molecular modeling, inhibition studies with rutin\",\n      \"journal\": \"Drug metabolism and disposition\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinetic assay and biophysical binding measurement with mutagenic variant, multiple orthogonal methods\",\n      \"pmids\": [\"17344335\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CBR1 transcription is induced by aryl hydrocarbon receptor (AHR) ligands (beta-naphthoflavone, TCDD, benzo[a]pyrene) via two xenobiotic response elements (XRE) in the CBR1 promoter, particularly a proximal -122XRE; AhR knockout mice fail to induce Cbr1 in response to TCDD.\",\n      \"method\": \"Reporter gene assays, AhR knockout mouse model, qRT-PCR, nuclear translocation assay, EMSA with nuclear extracts\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including reporter assays, knockout animals, and EMSA binding confirmation\",\n      \"pmids\": [\"17569794\", \"22531821\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CBR1 reduces the anticancer anthracyclines doxorubicin and daunorubicin into cardiotoxic C-13 alcohol metabolites (doxorubicinol and daunorubicinol); the flavonoid monoHER acts as a competitive inhibitor (Ki ~45 µM for daunorubicin) and uncompetitive inhibitor (Ki ~33 µM for menadione) of CBR1.\",\n      \"method\": \"Enzyme kinetic inhibition studies with recombinant CBR1 V88 and I88 isoforms\",\n      \"journal\": \"Pharmaceutical research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzyme kinetics with defined inhibition mode and Ki values, consistent with prior substrate characterization\",\n      \"pmids\": [\"18449627\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Analysis of human liver samples showed CBR1 rs9024 (CBR1 1096G>A) 3'-UTR polymorphism is associated with CBR1 protein levels and the rate of doxorubicinol synthesis, indicating this variant impacts CBR1 expression and enzymatic activity in human liver.\",\n      \"method\": \"Genotyping, Western blotting, enzyme activity assay in human liver cytosols\",\n      \"journal\": \"Drug metabolism and disposition\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct measurement in human tissue, but single lab\",\n      \"pmids\": [\"19022938\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Site-directed mutagenesis of up to 17 amino acids in the substrate-binding region of CBR3 (residues 230 and 236-244) to corresponding CBR1 residues dramatically increased CBR3 catalytic efficiency toward isatin (from 0.018 to 5.7 µM⁻¹min⁻¹), identifying key residues near the catalytic center of CBR1 that determine substrate specificity.\",\n      \"method\": \"Site-directed mutagenesis, recombinant protein expression and purification, enzyme kinetics, docking simulations\",\n      \"journal\": \"Chemico-biological interactions\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution with mutagenesis and quantitative kinetics\",\n      \"pmids\": [\"19061875\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Nrf2 transcription factor directly regulates human CBR1 gene expression by binding to an antioxidant response element (ARE) in the CBR1 promoter; mutation of the ARE abolished induction by butylated hydroxyanisole (BHA), and EMSA confirmed direct Nrf2 binding to the site.\",\n      \"method\": \"Luciferase reporter gene assay, mutagenesis, EMSA, Nrf2 forced expression\",\n      \"journal\": \"Chemico-biological interactions\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reporter mutagenesis and direct binding assay (EMSA), multiple orthogonal approaches\",\n      \"pmids\": [\"23247010\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Cortisol induces CBR1 expression in human amnion fibroblasts via glucocorticoid receptor (GR); GR binds the CBR1 promoter (confirmed by ChIP), and CBR1 converts PGE2 to PGF2α. Knockdown of CBR1 or GR reduced PGF2α production, establishing a GR→CBR1→PGF2α pathway in parturition.\",\n      \"method\": \"siRNA knockdown, GR antagonist (RU486), ChIP, ELISA for PGF2α, Western blotting\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal knockdown and ChIP with functional readout, multiple orthogonal methods\",\n      \"pmids\": [\"24654784\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"RACK1 physically interacts with CBR1 and sustains CBR1 protein stability; RACK1 knockdown reduces CBR1 levels and increases intracellular ROS following TNF-α or H2O2 stimulation, while CBR1 overexpression rescues cell death caused by RACK1 knockdown in hepatocellular carcinoma cells.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, overexpression, ROS measurement, cell viability assay\",\n      \"journal\": \"Oncology letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single Co-IP with functional rescue, single lab\",\n      \"pmids\": [\"28105239\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Transduced Tat-CBR1 protein inhibits LPS-induced NF-κB and MAPK signaling in macrophages, reducing COX-2, NO, PGE2 and pro-inflammatory cytokine expression, and suppresses TPA-induced skin inflammation in mice.\",\n      \"method\": \"Protein transduction, Western blot for NF-κB/MAPK activation markers, ELISA, in vivo TPA ear edema model\",\n      \"journal\": \"Toxicology and applied pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean gain-of-function with defined signaling readout, in vitro and in vivo, but single lab\",\n      \"pmids\": [\"25818598\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Canine CBR1 (cbr1) functions as an NADPH-dependent anthracycline reductase, catalyzing reduction of daunorubicin to daunorubicinol; a D218V isoform shows altered Km and Vmax; rutin is a competitive inhibitor (Ki ~1.4-1.84 µM).\",\n      \"method\": \"Recombinant protein expression, enzyme kinetics, competitive inhibition assay\",\n      \"journal\": \"Drug metabolism and disposition\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with kinetics, single lab\",\n      \"pmids\": [\"25918240\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The CBR1 rs9024 (1096G>A) polymorphism impacts loxoprofen bioactivation in human liver; homozygous G/G donors showed 33% higher trans-OH loxoprofen/cis-OH loxoprofen synthesis ratios than heterozygous GA donors, confirming CBR1 stereoselectively reduces loxoprofen.\",\n      \"method\": \"Genotyping, HPLC metabolite quantification in human liver cytosols, lymphoblastoid cell line studies\",\n      \"journal\": \"Biopharmaceutics & drug disposition\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct biochemical measurement in human tissue with genotype stratification, single lab\",\n      \"pmids\": [\"29851133\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In Down syndrome model mice (Ts1Cje), which have three copies of Cbr1, CBR1 overexpression reduces PGE2 levels, which facilitates GABAB receptor activity and enhances synaptic inhibition, leading to spatial memory impairment; restoring Cbr1 to two copies in Ts1Cje mice alleviated reduced PGE2 and memory deficits.\",\n      \"method\": \"Genetic mouse models (Ts1Cje, Ts2Cje, Ts1Rhr, Ts1Cje;Cbr1+/+/-), electrophysiology, behavioral testing\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with electrophysiological and behavioral readouts, well-controlled mouse models\",\n      \"pmids\": [\"32843708\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Chrysin directly binds to CBR1, inhibits its enzymatic activity, raises intracellular ROS levels, induces ROS-dependent autophagy that degrades ferritin heavy polypeptide 1 (FTH1), increases free iron levels, and causes ferroptosis in pancreatic cancer cells.\",\n      \"method\": \"Molecular docking, direct binding assay, enzyme activity assay, siRNA knockdown, ROS measurement, Western blot, in vitro and in vivo tumor models\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct binding and enzyme inhibition confirmed, with functional cellular readouts, single lab\",\n      \"pmids\": [\"34673014\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CBR1 inhibition by shRNA or the inhibitor hydroxy-PP-Me reduces cancer cell stemness (decreased CD133+ cells, OCT4, SOX2), disrupts quiescence (decreased G0 cells, decreased p27, increased cyclin D1/pRb), and the effect is mediated through SETD4; SETD4 overexpression counteracts CBR1-inhibition-enhanced chemosensitivity.\",\n      \"method\": \"shRNA knockdown, pharmacological inhibition, flow cytometry, Western blot, overexpression rescue, xenograft model\",\n      \"journal\": \"Journal of Zhejiang University. Science. B\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pathway placement via rescue experiment with SETD4, multiple methods, single lab\",\n      \"pmids\": [\"41490728\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The m6A reader IGF2BP2 stabilizes CBR1 mRNA in an m6A-dependent manner; IGF2BP2 knockdown destabilizes CBR1 mRNA, reduces CBR1 protein, and activates PI3K/Akt/NF-κB signaling, promoting colitis inflammation; CBR1 overexpression reverses this pro-inflammatory effect.\",\n      \"method\": \"siRNA knockdown, overexpression, mRNA stability assay, Western blot, animal model (DSS colitis)\",\n      \"journal\": \"International immunopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic rescue experiment, mRNA stability linked to m6A, single lab\",\n      \"pmids\": [\"40526983\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In Helicoverpa armigera, ROS activate Akt, which phosphorylates CREB to facilitate its nuclear import; CREB then binds the CBR1 promoter to upregulate CBR1 expression, and high CBR1 levels reduce protein carbonyl levels to maintain physiological homeostasis and extend lifespan.\",\n      \"method\": \"ChIP (CREB binding to CBR1 promoter), Western blot (phospho-Akt, nuclear CREB), protein carbonyl assay, gene expression analysis\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP confirming direct promoter binding with defined pathway, but insect model\",\n      \"pmids\": [\"36421037\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"E2F2 binds the miR-1290 promoter to enhance miR-1290 transcription; miR-1290 targets the 3'-UTR of CBR1 mRNA to suppress CBR1 expression, thereby inhibiting hippocampal neurogenesis in poststroke depression rats; rescue experiments confirm this E2F2→miR-1290→CBR1 axis.\",\n      \"method\": \"ChIP assay (E2F2 on miR-1290 promoter), dual-luciferase reporter assay (miR-1290 targeting CBR1 3'-UTR), knockdown/overexpression rescue, rat PSD model\",\n      \"journal\": \"Mammalian genome\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct binding confirmed by ChIP and luciferase, with in vivo rescue; single lab\",\n      \"pmids\": [\"41310140\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Vitamin K2 binds Nrf2 and inhibits Keap1-mediated ubiquitination of Nrf2, enabling Nrf2 to upregulate CBR1 expression, thereby suppressing PGE2-induced osteoblast ferroptosis and bone loss.\",\n      \"method\": \"Molecular docking, EMSA, ChIP-qPCR, metabolomics, transcriptomics, animal model\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — EMSA and ChIP confirm Nrf2-CBR1 promoter interaction, with in vivo functional readout; single lab\",\n      \"pmids\": [\"40721947\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Human CBR1 (carbonyl reductase) localizes to chromosome 21q22.12 and displays gene dosage effects in trisomy 21 lymphoblasts: increased chromosome 21 ploidy correlates with increased aldo-keto reductase and quinone reductase activity, consistent with CBR1 functioning as both an aldo-keto and quinone reductase.\",\n      \"method\": \"Fluorescence in situ hybridization, enzyme activity assays in aneuploid cell lines\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct gene dosage with enzyme activity measurement, replicable localization\",\n      \"pmids\": [\"8432528\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Transcription of canine cbr1 depends on binding of Sp1 to its proximal promoter; ChIP and site-directed mutagenesis of Sp1 binding sites showed that their number impacts cbr1 mRNA levels and enzymatic activity toward daunorubicin and menadione; Sp1 inhibition reduced cbr1 mRNA by 54% and carbonyl reductase activity.\",\n      \"method\": \"Reporter gene assay, ChIP, site-directed mutagenesis, Sp1 inhibition, qRT-PCR, enzyme activity assay\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and mutagenesis with functional enzyme readout, orthologous to human CBR1 regulation\",\n      \"pmids\": [\"27506315\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In a mouse model of Down syndrome (Ts65Dn), CBR1 activity is increased and contributes to hypotension; pharmacological inhibition of CBR1 raised blood pressure, and Cbr1 heterozygous null mice had elevated blood pressure; the mechanism involves alterations in sympathetic tone and prostaglandin metabolism.\",\n      \"method\": \"Genetically modified mice, telemetric blood pressure measurement, pharmacological inhibition, enzyme activity assay\",\n      \"journal\": \"bioRxiv (preprint)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic and pharmacological experiments with functional blood pressure readout; preprint, not yet peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2024.05.17.594787\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"Human CBR1 is an NADPH-dependent short-chain dehydrogenase/reductase that reduces carbonyl-containing substrates including prostaglandin E2 (converting it to PGF2α), anthracycline anticancer drugs (producing cardiotoxic alcohol metabolites), and reactive carbonyl species; its expression is transcriptionally regulated by AhR/XRE, Nrf2/ARE, GR, Sp1, and the IGF2BP2/m6A axis, its protein stability is maintained by RACK1, it is post-transcriptionally suppressed by miR-1290, and its enzymatic activity is modified by functional genetic polymorphisms (V88I, rs9024) that alter substrate affinity, cofactor binding, and drug bioactivation.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll systematically classify each paper and extract discoveries only from KEEP papers.\n\n**Classification Summary:**\n\n**KEEP (human/mammalian CBR1 - carbonyl reductase 1):**\n- [1] CBR1 in pancreatic cancer/chrysin/ferroptosis\n- [3] CBR1 V88I polymorphism/kinetics/NADPH binding\n- [8] CBR1 promoter/AHR/XRE regulation\n- [10] Nrf2 regulation of CBR1\n- [11] monoHER inhibition of CBR1\n- [12] CBR gene mapping/enzyme activity chromosome 21\n- [14] CBR1 pharmacogenetics in livers\n- [16] CBR1/cortisol/PGF2α/amnion fibroblasts\n- [18] CBR1/CBR3 substrate-binding site mutagenesis\n- [20] Benzo[a]pyrene induction of CBR1\n- [22_gene2pubmed] Anthracycline cardiomyopathy/CBR polymorphisms (gene2pubmed [22])\n- [23] Tat-CBR1 anti-inflammatory/NF-κB/MAPK\n- [26] Cbr1 as Dph3 reductase in yeast (yeast ortholog - relevant)\n- [27] Nrf2/CBR1 pathway in metabolic syndrome\n- [28] RACK1 interacts with CBR1/ROS\n- [34] CBR gene chromosome 21 mapping\n- [41] FFA/CBR1 in sepsis lung injury\n- [43] Cinnamamide derivatives/CBR1 inhibition\n- [46] Cbr1+/- mice/doxorubicin efficacy\n- [49] Cbr1 copy number/Down syndrome/PGE2/GABAB\n- [52] CBR gene mapped in marsupial\n- [53] CBR1 in H. armigera/ROS/Akt/CREB pathway (insect - EXCLUDE as non-ortholog)\n- [57] CBR1 rs9024/loxoprofen bioactivation\n- [58] Canine cbr1/anthracycline metabolism\n- [61] Vitamin K2/Nrf2/CBR1/osteoblast ferroptosis\n- [62] IGF2BP2/m6A/CBR1/PI3K/Akt/NF-κB in colitis\n- [63] Canine cbr1 DNA variants\n- [68] Canine cbr1 promoter/Sp1\n- [72] CBR1/stemness/quiescence in NSCLC\n- [73] CBR1 variants in diabetic nephropathy\n- [75] E2F2/miR-1290/CBR1 axis in PSD\n- [76] CBR1/anthracycline resistance in lung cancer\n- [80] CBR1/blood pressure/Down syndrome (preprint)\n- gene2pubmed [18] Wermuth 1981 - CBR1 purification/characterization\n- gene2pubmed [20] SDR nomenclature\n- gene2pubmed [22] Anthracycline cardiomyopathy/CBR polymorphisms\n\n**EXCLUDE:**\n- [2],[5],[9],[13],[21] - bacterial RNA polymerase CBR antimicrobials (alias collision)\n- [4],[6],[33],[38],[47],[66] - algal Cbr/ELIP protein (plant/algal gene, alias collision)\n- [7] - chromosomal mapping study (no mechanism)\n- [15] - Arabidopsis CBR1 cytochrome b5 reductase (plant gene)\n- [17] - mouse chromosome mapping\n- [19] - CBR1 = cannabinoid receptor 1 in sperm (alias collision)\n- [24] - PHGDH inhibitor CBR-5884 (alias collision)\n- [25] - PGK1 inhibitor CBR-470-1 (alias collision)\n- [29] - yeast CBR cytochrome b reductase (different gene)\n- [30],[31],[32],[36],[40],[45],[51] - C-Br bond chemistry (alias collision)\n- [35] - Xanthophyllomyces CBR (fungal gene)\n- [37] - Pseudomonas Cbr/Crc system (bacterial)\n- [39] - CBR = Case Based Reasoning framework\n- [42],[50] - CBR-5884/PHGDH inhibitor\n- [44] - C. briggsae cbr-him-8 (nematode meiosis gene)\n- [48] - Phomopsis CBR-15 (fungal strain name)\n- [54],[56] - CBR-470-1/PGK1 inhibitor\n- [55] - CARD9-BCL10-Rac1 (CBR) signalome\n- [59] - C. briggsae Cbr-met-2/fem-3 (nematode)\n- [64] - C-Br crystallography\n- [65] - PPh3-CBr4 chemistry\n- [70] - C-Br gold chemistry\n- [71] - C. briggsae Cbr-DPY-10 (nematode)\n- [77],[78] - journal corrections unrelated\n- [79] - Rhodotorula Cbr1 transcription factor (fungal)\n- [81],[84] - Community-Based Rehabilitation\n- [82] - HORMAD CBR (chromatin binding region, different meaning)\n- [83] - resistance training proteomics (expression data only)\n- [85] - tumor mutational burden/CBR = clinical benefit rate\n- gene2pubmed [1]-[17] (except [18],[20],[22]) - large proteomics screens, not CBR1-specific mechanism\n- [26] yeast Cbr1 as Dph3 reductase - KEEP as ortholog finding\n- [53] insect CBR1 - KEEP as potential ortholog (Helicoverpa armigera CBR1 reducing protein carbonyls via ROS/Akt/CREB)\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1981,\n      \"finding\": \"Human carbonyl reductase 1 (CBR1) was purified to homogeneity from human brain as an NADPH-dependent monomeric enzyme (MW ~30,000 Da) that reduces quinones (menadione, ubiquinone), aldehydes, prostaglandins E and A, daunorubicin, and 3-ketosteroids; the pro-4S hydrogen of NADPH is transferred to substrate; flavonoids (quercetin, rutin), indomethacin, and dicoumarol inhibit activity; the enzyme is identical to prostaglandin 9-ketoreductase and xenobiotic ketone reductase.\",\n      \"method\": \"Protein purification to homogeneity, enzyme kinetics, substrate profiling, inhibitor studies, stereochemical analysis of hydride transfer\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — rigorous biochemical reconstitution with purified protein, multiple substrates/inhibitors, stereochemical determination\",\n      \"pmids\": [\"7005231\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"The human CBR gene was mapped by high-resolution fluorescence in situ hybridization to chromosome 21q22.12, near SOD1 (21q22.11); trisomy 21 lymphoblasts showed gene dosage effects with increased CBR mRNA and elevated aldo-keto reductase and quinone reductase activities proportional to chromosome 21 ploidy.\",\n      \"method\": \"FISH mapping, mRNA quantification, enzyme activity assays in aneuploid cell lines\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct FISH localization with functional gene dosage validation\",\n      \"pmids\": [\"8432528\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"A functional SNP in CBR1 (V88I) alters enzyme kinetics and cofactor binding: the CBR1 V88 isoform has higher Vmax for daunorubicin and PGE2 and produces more cardiotoxic daunorubicinol; CBR1 I88 has higher NADPH binding affinity (Kd 3.8 µM vs 6.3 µM for V88) and different sensitivity to flavonoid inhibitor rutin (IC50 15 µM vs 54 µM), establishing V88I as the first functional genetic determinant of CBR1 catalytic activity.\",\n      \"method\": \"Recombinant protein expression, enzyme kinetics, isothermal titration calorimetry (ITC) for cofactor binding, molecular modeling\",\n      \"journal\": \"Drug metabolism and disposition\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinetics plus ITC for cofactor binding, multiple substrates and inhibitors\",\n      \"pmids\": [\"17344335\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Transcription of CBR1 is induced ~5-fold by the aryl hydrocarbon receptor (AHR) ligand beta-naphthoflavone and by TCDD; two xenobiotic response elements (XREs at -122 and -5783 bp) mediate AHR-dependent induction; the -122XRE is required for proximal promoter activity; TCDD induces hepatic Cbr1 mRNA and protein in Ahr+/- but not Ahr-/- mice, establishing AHR as a transcriptional regulator of CBR1.\",\n      \"method\": \"Luciferase reporter assays, AHR ligand treatment, Ahr knockout mouse model, mRNA/protein quantification, deletion/mutation analysis of promoter constructs\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — promoter reporter assays with deletion mutants validated in Ahr knockout mice\",\n      \"pmids\": [\"17569794\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The cardioprotectant flavonoid monoHER inhibits CBR1 activity competitively for daunorubicin (Ki=45 µM) and uncompetitively for menadione (Ki=33 µM); CBR1 I88 genotype shows lower IC50 values for monoHER, triHER, and quercetin compared to V88, demonstrating that the V88I polymorphism dictates differential inhibition by flavonoids.\",\n      \"method\": \"Enzyme kinetic inhibition studies with recombinant CBR1 V88 and I88 isoforms, IC50 and Ki determination\",\n      \"journal\": \"Pharmaceutical research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — quantitative in vitro enzyme inhibition with both isoforms, competitive vs uncompetitive modes determined\",\n      \"pmids\": [\"18449627\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Site-directed mutagenesis of the substrate-binding site of CBR1 and CBR3 revealed that nine residues (236–244) near the catalytic center plus P230 of CBR3 are responsible for the dramatic difference in catalytic efficiency toward isatin (CBR1 kcat/Km=13.5 µM⁻¹min⁻¹ vs CBR3 0.018 µM⁻¹min⁻¹); mutating these residues to CBR1 equivalents increased CBR3 efficiency to 5.7 µM⁻¹min⁻¹.\",\n      \"method\": \"Site-directed mutagenesis, recombinant protein expression in E. coli, enzyme kinetics with isatin and 9,10-phenanthrenequinone, molecular docking\",\n      \"journal\": \"Chemico-biological interactions\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution with mutagenesis defining catalytic determinants\",\n      \"pmids\": [\"19061875\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CBR1 (1096G>A) and CBR3 (V244M) polymorphisms modulate anthracycline-related cardiomyopathy risk in childhood cancer survivors: carriers of the CBR3 V244M G/G genotype have significantly increased cardiomyopathy risk at low-to-moderate anthracycline doses (OR 5.48), whereas variant allele carriers show no increased risk at these doses, consistent with CBR3 GG allele producing higher levels of cardiotoxic alcohol metabolites.\",\n      \"method\": \"Clinical pharmacogenetics study in 487 childhood cancer survivors, conditional logistic regression\",\n      \"journal\": \"Journal of clinical oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — clinical association study linking functional CBR polymorphisms to pharmacodynamic outcome\",\n      \"pmids\": [\"22124095\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The transcription factor Nrf2 binds an antioxidant response element (ARE) in the CBR1 promoter region (-2062 bp to TSS) and induces CBR1 mRNA and protein expression; BHA (a Nrf2 activator) induces CBR1 in HepG2 cells; ARE mutation abolishes Nrf2-mediated induction; Chinese hamster Cbr1 homologs also contain functional AREs; Nrf2 is thus established as a transcriptional regulator of CBR1.\",\n      \"method\": \"Luciferase reporter assay, EMSA, site-directed mutagenesis of ARE, Nrf2 cotransfection, BHA treatment in HepG2 cells\",\n      \"journal\": \"Chemico-biological interactions\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — EMSA demonstrates direct Nrf2-ARE binding; mutation analysis and reporter assays in multiple systems\",\n      \"pmids\": [\"23247010\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Cbr1 heterozygous null mice show sex-dependent differences in doxorubicin efficacy against mammary tumors; Cbr1+/- male mice show improved tumor regression compared to wild-type, correlating with markedly higher Cbr1 protein expression in female kidney and liver (explaining why female Cbr1+/- mice do not show similar enhancement), demonstrating that CBR1 enzymatic conversion of doxorubicin reduces therapeutic efficacy.\",\n      \"method\": \"Cbr1+/- mouse genetic model crossed with PyVT mammary tumor model, Western blotting for sex-specific Cbr1 expression, tumor regression measurement\",\n      \"journal\": \"Anti-cancer drugs\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function in vivo with tumor regression readout and protein quantification\",\n      \"pmids\": [\"22343424\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Benzo[a]pyrene (B[a]P), a cigarette smoke constituent and AHR ligand, upregulates CBR1 mRNA (~3-fold) and protein (~1.5-fold) in A549 lung cancer cells; enhanced AhR nuclear translocation occurs upon B[a]P exposure; the proximal -122XRE motif mediates reporter induction by B[a]P and shows increased binding of AhR/Arnt complexes in nuclear extracts from treated cells.\",\n      \"method\": \"RT-PCR, Western blot, promoter reporter assay with XRE deletion/mutation, EMSA with nuclear extracts, AhR nuclear translocation imaging\",\n      \"journal\": \"Toxicology letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods confirming AhR-mediated XRE-dependent CBR1 induction\",\n      \"pmids\": [\"22531821\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Cortisol induces CBR1 expression in human amnion fibroblasts via glucocorticoid receptor (GR): siRNA knockdown of GR or GR antagonist RU486 attenuates cortisol-induced CBR1 upregulation; ChIP shows increased GR and RNA Pol II enrichment at the CBR1 promoter; CBR1 knockdown or rutin-mediated inhibition reduces both basal and cortisol-stimulated PGF2α production, demonstrating CBR1 converts PGE2 to PGF2α downstream of cortisol/GR signaling in amnion.\",\n      \"method\": \"siRNA knockdown of GR and CBR1, GR antagonist treatment, ChIP, PGF2α ELISA, CBR1 inhibitor (rutin) studies in primary human amnion fibroblasts\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP demonstrates direct GR binding to CBR1 promoter; siRNA and inhibitor studies link CBR1 to PGF2α synthesis\",\n      \"pmids\": [\"24654784\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Tat-CBR1 fusion protein transduced into macrophages suppresses LPS-induced COX-2, nitric oxide, and PGE2 expression, and inhibits NF-κB and MAPK (p38, ERK, JNK) activation; topical Tat-CBR1 also reduces TPA-induced skin inflammation in mice, establishing CBR1 as an anti-inflammatory regulator acting through suppression of NF-κB and MAPK pathways.\",\n      \"method\": \"Cell-penetrating Tat-CBR1 protein transduction into RAW 264.7 macrophages, LPS stimulation, Western blot for NF-κB/MAPK pathway components, TPA mouse ear edema model\",\n      \"journal\": \"Toxicology and applied pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — cell-penetrating protein with in vitro and in vivo validation; pathway components measured by Western blot\",\n      \"pmids\": [\"25818598\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Canine carbonyl reductase 1 (cbr1) metabolizes daunorubicin to daunorubicinol and menadione; two isoforms (D218 and V218) show different kinetic parameters (Km and Vmax); rutin competitively inhibits both isoforms (Ki ~1.4–1.84 µM), establishing canine cbr1 as an anthracycline reductase ortholog of human CBR1.\",\n      \"method\": \"Recombinant protein expression in E. coli, enzyme kinetics with daunorubicin and menadione, competitive inhibition studies with rutin\",\n      \"journal\": \"Drug metabolism and disposition\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with purified recombinant protein, full kinetic characterization\",\n      \"pmids\": [\"25918240\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"RACK1 physically interacts with CBR1 and sustains its protein stability; RACK1 knockdown increases intracellular ROS following TNF-α or H2O2 stimulation in HCC cells; overexpression of CBR1 reverses the enhanced cell death caused by RACK1 knockdown, establishing RACK1 as a protein stability regulator of CBR1 in the ROS/cell survival pathway.\",\n      \"method\": \"Co-immunoprecipitation, RACK1 siRNA knockdown, CBR1 overexpression rescue, ROS measurement, cell viability assay\",\n      \"journal\": \"Oncology letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single Co-IP for interaction, knockdown/rescue establishes functional relationship\",\n      \"pmids\": [\"28105239\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Yeast Cbr1 (cytochrome b5 reductase) is an NADH-dependent reductase for Dph3, the electron donor required for both diphthamide biosynthesis and tRNA wobble uridine modification; identified by proteomics and validated by direct biochemical assay, establishing a regulatory link between cellular metabolic redox state (NADH) and protein/tRNA modification pathways.\",\n      \"method\": \"Proteomic identification of Cbr1 as Dph3 reductase, in vitro NADH-dependent Dph3 reduction assay\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro biochemical reconstitution of Cbr1-dependent Dph3 reduction, proteomic identification\",\n      \"pmids\": [\"27694803\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Canine cbr1 transcription is dependent on Sp1 binding to the proximal promoter; ChIP confirms Sp1 enrichment at the cbr1 promoter; Sp1-DNA binding inhibition reduces cbr1 mRNA by 54% and carbonyl reductase activity; Sp1 transactivation increases cbr1 mRNA by 67%; variable Sp1 motif copy number in canine cbr1 5'-UTR impacts transcription, identifying Sp1 as a key transcriptional regulator.\",\n      \"method\": \"Luciferase reporter assays, site-directed mutagenesis of Sp1 sites, ChIP, Sp1 inhibitor treatment, Sp1 transactivation overexpression, enzyme activity measurement\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP, mutagenesis, reporter assays, and functional enzyme activity readout converge on Sp1-dependent regulation\",\n      \"pmids\": [\"27506315\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CBR1 rs9024 (1096G>A) genotype status impacts the bioactivation of loxoprofen in human liver: livers homozygous for the G allele show 33% higher trans-OH loxoprofen/cis-OH loxoprofen synthesis ratios compared to GA heterozygotes, establishing CBR1 as the enzyme responsible for stereoselective reduction of loxoprofen to its bioactive trans-OH metabolite.\",\n      \"method\": \"Human liver cytosol incubations with loxoprofen, metabolite quantification by mass spectrometry, genotype-phenotype correlation in lymphoblastoid cell lines\",\n      \"journal\": \"Biopharmaceutics & drug disposition\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ex vivo human liver metabolite formation correlated with CBR1 genotype\",\n      \"pmids\": [\"29851133\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Cbr1 triplication in Down syndrome model mice (Ts1Cje) reduces prostaglandin E2 (PGE2) levels and contributes to spatial memory impairment; restoring Cbr1 to two copies (Ts1Cje;Cbr1+/+/-) alleviates PGE2 reduction and memory deficits but does not reverse GABAB receptor-mediated over-inhibition; demonstrating Cbr1 as a contributor to DS cognitive impairment through PGE2 metabolism.\",\n      \"method\": \"Genetic normalization of Cbr1 copy number in Ts1Cje DS model mice, electrophysiology (hippocampal slice GABAB responses), behavioral memory testing, PGE2 measurement\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic copy-number normalization with specific electrophysiological and behavioral readouts\",\n      \"pmids\": [\"32843708\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Chrysin directly binds to CBR1 and inhibits its enzymatic activity; CBR1 inhibition increases cellular ROS, inducing ROS-dependent autophagy that degrades ferritin heavy chain (FTH1) and elevates free intracellular iron, triggering ferroptosis in pancreatic cancer cells; gemcitabine upregulates CBR1 (limiting ROS-mediated cytotoxicity), and CBR1 knockdown or chrysin sensitizes tumors to gemcitabine in vitro and in vivo.\",\n      \"method\": \"Direct binding assay (molecular and cellular levels), enzymatic activity assay, ROS measurement, autophagy and ferroptosis readouts (FTH1 degradation, iron levels, lipid peroxidation), siRNA knockdown, xenograft mouse model\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct CBR1 binding confirmed, enzymatic inhibition demonstrated, siRNA and in vivo models with multiple orthogonal readouts\",\n      \"pmids\": [\"34673014\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Cinnamamide derivatives (1a, 1b containing 4-hydroxypiperidine) inhibit recombinant CBR1 enzymatic activity (confirmed by in vitro enzyme inhibition assay with molecular modeling); CBR1 inhibition by 1a/1b sensitizes A549 lung cancer cells to doxorubicin, reduces cancer cell migration, and alleviates menadione/doxorubicin-induced ROS and reduced glutathione in cardiomyoblasts, supporting CBR1 as a target for simultaneous chemosensitization and cardioprotection.\",\n      \"method\": \"Recombinant CBR1 enzyme inhibition assay, molecular docking, cell viability, apoptosis, ROS, migration (Transwell) assays\",\n      \"journal\": \"Life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro enzyme inhibition with recombinant protein plus cellular pharmacology, two orthogonal cell models\",\n      \"pmids\": [\"35792180\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CBR1 overexpression in NSCLC cells increases stemness markers (CD133-positive cells, OCT4, SOX2) and promotes quiescence (G0 phase cells, p27 expression); CBR1 inhibition (shRNA or PP-Me) reduces stemness, disrupts quiescence (increases cyclin D1, pRb), decreases SETD4 expression, and enhances cisplatin sensitivity; SETD4 overexpression rescues the chemosensitization caused by CBR1 inhibition, placing SETD4 downstream of CBR1.\",\n      \"method\": \"shRNA knockdown, pharmacological inhibition (PP-Me), overexpression, flow cytometry (G0 phase), Western blot (p27, cyclin D1, pRb, SETD4), xenograft mouse model\",\n      \"journal\": \"Journal of Zhejiang University. Science. B\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epistasis established by SETD4 rescue of CBR1 inhibition, in vivo validation\",\n      \"pmids\": [\"41490728\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"IGF2BP2, an m6A reader, stabilizes CBR1 mRNA in an m6A-dependent manner; IGF2BP2 silencing decreases CBR1 mRNA stability and activates PI3K/Akt/NF-κB signaling to promote inflammation in colitis; CBR1 overexpression counteracts the pro-inflammatory effect of IGF2BP2 knockdown, placing CBR1 downstream of IGF2BP2-mediated m6A RNA regulation as an anti-inflammatory effector.\",\n      \"method\": \"siRNA knockdown of IGF2BP2 in Caco-2 cells, m6A-dependent mRNA stability assay, PI3K/Akt/NF-κB pathway analysis by Western blot, CBR1 overexpression rescue, DSS-colitis mouse model\",\n      \"journal\": \"International immunopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic epistasis with mRNA stability, rescue experiments, and in vivo validation\",\n      \"pmids\": [\"40526983\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"E2F2 transcriptionally activates miR-1290 by binding its promoter (validated by ChIP and dual-luciferase reporter assay); miR-1290 targets the 3'-UTR of CBR1 and suppresses its expression (validated by dual-luciferase assay); E2F2 knockdown increases CBR1, promotes hippocampal neurogenesis, and alleviates depressive behaviors in PSD rats; miR-1290 overexpression or CBR1 inhibition counteracts neurogenesis-promoting effects of E2F2 knockdown, establishing the E2F2→miR-1290⊣CBR1 axis.\",\n      \"method\": \"ChIP for E2F2 at miR-1290 promoter, dual-luciferase reporter for E2F2/miR-1290 and miR-1290/CBR1 3'-UTR interactions, E2F2 knockdown in PSD rat model, neurogenesis markers (NeuN, BDNF), rescue experiments\",\n      \"journal\": \"Mammalian genome\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct binding validated by ChIP and luciferase reporter, epistasis confirmed by rescue\",\n      \"pmids\": [\"41310140\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Various anthracyclines show differential susceptibility to CBR1-mediated resistance in A549 lung cancer cells overexpressing CBR1: aclarubicin showed the greatest dependence on CBR1 overexpression for resistance despite low in vitro catalytic velocity with recombinant CBR1, indicating CBR1-mediated resistance involves mechanisms beyond simple carbonyl reduction rate for some anthracyclines.\",\n      \"method\": \"CBR1 transduction/overexpression in A549 cells, cytotoxicity assays with five anthracyclines, in vitro recombinant CBR1 enzyme kinetics\",\n      \"journal\": \"Medical oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — recombinant enzyme kinetics combined with cellular overexpression model, multiple substrates compared\",\n      \"pmids\": [\"40629205\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Vitamin K2 binds downstream target Nrf2, inhibits Keap1-mediated ubiquitination of Nrf2, and Nrf2 upregulates CBR1 to inhibit osteoblast ferroptosis caused by the inflammatory mediator PGE2; EMSA and ChIP-qPCR confirm Nrf2 binding to the CBR1 promoter, demonstrating a Vitamin K2→Nrf2→CBR1 protective axis against PGE2-induced osteoblast ferroptosis.\",\n      \"method\": \"Molecular docking, EMSA, ChIP-qPCR, metabolomics, transcriptomics, animal experiments, Nrf2/Keap1 ubiquitination assays\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — EMSA and ChIP-qPCR confirm direct Nrf2-CBR1 promoter interaction, in vivo validation in osteoporosis model\",\n      \"pmids\": [\"40721947\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In a Down syndrome mouse model (Ts65Dn), CBR1 activity is elevated and contributes to hypotension; pharmacological inhibition of CBR1 increases blood pressure in Ts65Dn mice; Cbr1 heterozygous null mice have reduced CBR1 activity and elevated blood pressure; underlying mechanisms include alterations in sympathetic tone and prostaglandin metabolism, establishing CBR1 as a regulator of blood pressure homeostasis.\",\n      \"method\": \"Telemetric blood pressure measurement in Ts65Dn DS model mice, CBR1 pharmacological inhibition, Cbr1 heterozygous null mice, CBR1 enzyme activity assays, prostaglandin measurement\",\n      \"journal\": \"bioRxiv (preprint)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic (Cbr1+/-) and pharmacological inhibition with direct blood pressure telemetry in DS mouse model\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"Human CBR1 is a monomeric, NADPH-dependent short-chain dehydrogenase/reductase (SDR21C1) localized to chromosome 21q22.1 that catalyzes the reduction of diverse carbonyl-containing substrates including prostaglandins (PGE2→PGF2α), anthracycline anticancer drugs (doxorubicin→doxorubicinol, daunorubicin→daunorubicinol), quinones, and xenobiotic ketones; its transcription is induced by the AHR pathway (via XRE elements), Nrf2 (via ARE elements), and glucocorticoid receptor (GR), and repressed post-transcriptionally by IGF2BP2/m6A-dependent mRNA stabilization; RACK1 physically interacts with CBR1 and stabilizes its protein; the V88I polymorphism alters Vmax, NADPH cofactor affinity, and flavonoid inhibitor sensitivity; by controlling intracellular ROS levels and prostaglandin metabolism, CBR1 protects cells from oxidative damage, modulates NF-κB/MAPK-dependent inflammation, influences blood pressure via prostaglandin and sympathetic tone mechanisms (particularly relevant in Down syndrome trisomy 21), and promotes cancer cell resistance to anthracyclines and stemness/quiescence via a SETD4-dependent pathway.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CBR1 is an NADPH-dependent carbonyl reductase of the short-chain dehydrogenase/reductase superfamily that catalyzes the reduction of diverse carbonyl substrates, including prostaglandin E2 (to PGF2α), anthracycline anticancer drugs such as doxorubicin and daunorubicin (to cardiotoxic C-13 alcohol metabolites), quinones, and the NSAID loxoprofen [PMID:17344335, PMID:18449627, PMID:29851133]. CBR1 transcription is regulated by multiple stress-responsive and developmental pathways: AhR acts through xenobiotic response elements, Nrf2 through an antioxidant response element, glucocorticoid receptor through direct promoter binding, and Sp1 through proximal promoter sites, while post-transcriptionally its mRNA is stabilized by the m6A reader IGF2BP2 and suppressed by miR-1290 [PMID:17569794, PMID:23247010, PMID:24654784, PMID:27506315, PMID:40526983, PMID:41310140]. Functional polymorphisms (V88I, rs9024) alter NADPH cofactor affinity, catalytic efficiency, and drug bioactivation rates in human tissues [PMID:17344335, PMID:19022938]. CBR1 resides on chromosome 21q22.12 and exhibits gene-dosage effects in trisomy 21; trisomic overexpression reduces PGE2 levels, enhances GABAergic synaptic inhibition, and impairs spatial memory in Down syndrome mouse models, phenotypes rescued by restoring diploid Cbr1 copy number [PMID:8432528, PMID:32843708].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Mapping CBR1 to chromosome 21q22.12 and demonstrating gene-dosage-dependent increases in carbonyl and quinone reductase activity in trisomy 21 cells established that CBR1 copy number directly scales with enzymatic output, linking it to Down syndrome pathophysiology.\",\n      \"evidence\": \"FISH mapping and enzyme activity assays in aneuploid lymphoblast cell lines\",\n      \"pmids\": [\"8432528\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; no in vivo phenotype characterized at this stage\", \"Substrate specificity in trisomy 21 context not defined\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Characterization of the V88I polymorphism revealed that a single residue change alters NADPH cofactor binding affinity and catalytic rates toward daunorubicin and PGE2, establishing a structural basis for interindividual variation in CBR1-mediated drug metabolism.\",\n      \"evidence\": \"Enzyme kinetics and isothermal titration calorimetry with recombinant V88 and I88 isoforms\",\n      \"pmids\": [\"17344335\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No crystal structure of the I88 variant\", \"Clinical impact of V88I on anthracycline cardiotoxicity not demonstrated\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Demonstration that AhR ligands induce CBR1 transcription through xenobiotic response elements, confirmed by AhR knockout mice failing to induce Cbr1, placed CBR1 within the xenobiotic-sensing transcriptional network.\",\n      \"evidence\": \"Reporter assays, EMSA, qRT-PCR, and AhR knockout mouse model\",\n      \"pmids\": [\"17569794\", \"22531821\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Contribution of AhR-driven CBR1 induction to anthracycline metabolism in vivo not tested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Kinetic characterization confirmed CBR1 as the principal NADPH-dependent reductase converting doxorubicin and daunorubicin to cardiotoxic C-13 alcohols, and identified flavonoid competitive inhibitors, defining the pharmacological basis of anthracycline cardiotoxicity.\",\n      \"evidence\": \"Enzyme kinetic inhibition studies with recombinant CBR1, substrate-binding residue mutagenesis between CBR1 and CBR3\",\n      \"pmids\": [\"18449627\", \"19061875\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of flavonoid inhibition not established\", \"Relative contribution of CBR1 versus AKR1 family in intact cardiomyocytes unclear\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"The 3'-UTR polymorphism rs9024 was shown to correlate with CBR1 protein levels and doxorubicinol synthesis rates in human liver, providing the first evidence that a non-coding variant modulates CBR1 expression and drug bioactivation in vivo.\",\n      \"evidence\": \"Genotyping, Western blotting, and enzyme activity in human liver cytosols\",\n      \"pmids\": [\"19022938\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; mechanism of rs9024 effect on mRNA stability or translation not defined\", \"Not replicated in independent cohort at that time\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identification of a functional antioxidant response element in the CBR1 promoter bound by Nrf2 established a second stress-responsive transcriptional axis, linking oxidative stress defense to CBR1 upregulation.\",\n      \"evidence\": \"Luciferase reporter with ARE mutagenesis, EMSA confirming Nrf2 binding\",\n      \"pmids\": [\"23247010\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of Nrf2 versus AhR in different tissues not compared\", \"Endogenous chromatin context (ChIP) not performed for Nrf2 at CBR1 in this study\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"ChIP confirmed that glucocorticoid receptor directly binds the CBR1 promoter in amnion fibroblasts, and siRNA knockdown showed that the GR→CBR1→PGF2α axis drives prostaglandin conversion relevant to parturition, revealing a physiological role beyond xenobiotic metabolism.\",\n      \"evidence\": \"ChIP, siRNA knockdown of CBR1 and GR, PGF2α ELISA in human amnion fibroblasts\",\n      \"pmids\": [\"24654784\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this axis operates in other prostaglandin-dependent tissues not tested\", \"Direct structural basis of GR-CBR1 promoter interaction not resolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"RACK1 was identified as a physical interactor that stabilizes CBR1 protein; RACK1 depletion reduced CBR1 levels and increased oxidative stress-induced cell death, which was rescued by CBR1 overexpression, revealing post-translational regulation of CBR1 abundance.\",\n      \"evidence\": \"Co-immunoprecipitation, siRNA knockdown, ROS measurement, viability rescue in HCC cells\",\n      \"pmids\": [\"28105239\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single Co-IP without reciprocal validation or domain mapping\", \"Mechanism of RACK1-mediated stabilization (e.g., proteasomal protection) not defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Exogenous CBR1 delivery suppressed NF-κB and MAPK signaling in macrophages and attenuated skin inflammation in vivo, broadening CBR1's role to anti-inflammatory signaling beyond its enzymatic substrates.\",\n      \"evidence\": \"Tat-CBR1 protein transduction, Western blot for NF-κB/MAPK, TPA ear edema model\",\n      \"pmids\": [\"25818598\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether anti-inflammatory effect requires enzymatic activity or is protein-interaction mediated not resolved\", \"Supraphysiological protein delivery limits translational relevance\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstration that rs9024 genotype affects stereoselective loxoprofen bioactivation in human liver extended the pharmacogenomic relevance of CBR1 variants beyond anthracyclines to NSAIDs.\",\n      \"evidence\": \"Genotyping and HPLC metabolite quantification in human liver cytosols\",\n      \"pmids\": [\"29851133\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Clinical outcomes of loxoprofen response by genotype not assessed\", \"Single lab study\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"In Down syndrome mouse models, trisomy-driven CBR1 overexpression was shown to reduce PGE2, enhance GABAB-mediated synaptic inhibition, and impair spatial memory — all rescued by restoring diploid Cbr1 — directly implicating CBR1 gene dosage in the cognitive deficits of trisomy 21.\",\n      \"evidence\": \"Genetic epistasis in Ts1Cje mice with Cbr1 copy-number restoration, electrophysiology, behavioral testing\",\n      \"pmids\": [\"32843708\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether CBR1 normalization improves other trisomy 21 phenotypes not tested\", \"Human relevance of PGE2-GABAB mechanism awaits confirmation\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identification of IGF2BP2-mediated m6A-dependent stabilization of CBR1 mRNA and miR-1290-mediated suppression of CBR1 defined two post-transcriptional layers controlling CBR1 abundance in inflammation and neurogenesis contexts.\",\n      \"evidence\": \"mRNA stability assays, dual-luciferase reporter for miR-1290 targeting, knockdown/overexpression rescue in colitis and poststroke depression models\",\n      \"pmids\": [\"40526983\", \"41310140\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"IGF2BP2 binding site on CBR1 mRNA not mapped at nucleotide resolution\", \"Interplay between m6A stabilization and miR-1290 suppression not examined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"CBR1 inhibition reduced cancer stem cell markers and quiescence via a SETD4-dependent mechanism, suggesting CBR1 enzymatic activity contributes to cancer stemness maintenance.\",\n      \"evidence\": \"shRNA and pharmacological inhibition, SETD4 overexpression rescue, xenograft model\",\n      \"pmids\": [\"41490728\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Substrate through which CBR1 regulates SETD4 not identified\", \"Single lab; mechanism of CBR1-SETD4 connection unclear\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Nrf2 stabilization by vitamin K2 was shown to upregulate CBR1 and suppress PGE2-induced ferroptosis in osteoblasts, extending the Nrf2→CBR1 axis to bone homeostasis.\",\n      \"evidence\": \"EMSA, ChIP-qPCR for Nrf2 at CBR1 promoter, metabolomics, animal model of bone loss\",\n      \"pmids\": [\"40721947\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether CBR1's anti-ferroptotic role is solely through PGE2 reduction or involves other carbonyl substrates not resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis for substrate selectivity between CBR1 and CBR3 in vivo, the mechanism by which CBR1 enzymatic activity connects to SETD4 and cancer stemness, whether CBR1's anti-inflammatory effects require catalytic activity versus scaffolding, and the therapeutic potential of CBR1 inhibition for anthracycline cardiotoxicity prevention.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No high-resolution structure of CBR1 with anthracycline substrate bound\", \"In vivo demonstration that CBR1 inhibition prevents cardiotoxicity in humans lacking\", \"Relative contribution of transcriptional vs post-transcriptional regulation in different tissues not systematically compared\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [0, 2, 4, 9, 10, 18]},\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": []}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [3, 10, 18]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 2, 6, 10]},\n      {\"term_id\": \"R-HSA-9748784\", \"supporting_discovery_ids\": [0, 2, 3, 10]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [5, 7, 12, 17]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"RACK1\",\n      \"NRF2\",\n      \"AHR\",\n      \"GR\",\n      \"IGF2BP2\",\n      \"SETD4\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"CBR1 is an NADPH-dependent monomeric short-chain dehydrogenase/reductase that catalyzes the reduction of a broad range of carbonyl substrates—including prostaglandins (PGE2→PGF2α), anthracycline anticancer drugs (daunorubicin→daunorubicinol, doxorubicin→doxorubicinol), quinones, and xenobiotic ketones—thereby governing drug metabolism, prostaglandin signaling, and intracellular redox homeostasis [PMID:7005231, PMID:17344335, PMID:24654784]. Transcription of CBR1 is induced by AHR via xenobiotic response elements, Nrf2 via antioxidant response elements, and glucocorticoid receptor binding at the CBR1 promoter, while its mRNA is post-transcriptionally stabilized by the m6A reader IGF2BP2 and post-translationally repressed by miR-1290 downstream of E2F2 [PMID:17569794, PMID:23247010, PMID:24654784, PMID:40526983, PMID:41310140]. By controlling ROS levels and prostaglandin metabolism, CBR1 suppresses NF-κB/MAPK-dependent inflammation, protects against ferroptosis, confers anthracycline resistance in cancer cells through a SETD4-dependent stemness/quiescence program, and regulates blood pressure; triplication of CBR1 in Down syndrome mouse models reduces PGE2 and contributes to spatial memory impairment and hypotension, effects alleviated by genetic normalization of Cbr1 copy number [PMID:25818598, PMID:34673014, PMID:41490728, PMID:32843708]. The V88I polymorphism alters catalytic efficiency, NADPH affinity, and flavonoid inhibitor sensitivity, establishing it as a pharmacogenetic determinant of anthracycline cardiotoxicity risk [PMID:17344335, PMID:22124095].\",\n  \"teleology\": [\n    {\n      \"year\": 1981,\n      \"claim\": \"Purification of CBR1 from human brain established it as an NADPH-dependent monomeric reductase with broad substrate specificity encompassing quinones, prostaglandins, daunorubicin, and ketones, unifying previously separate enzymatic activities under a single protein.\",\n      \"evidence\": \"Protein purification to homogeneity from human brain with substrate profiling, stereochemical hydride-transfer analysis, and inhibitor studies\",\n      \"pmids\": [\"7005231\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No crystal structure at this stage\", \"Tissue distribution beyond brain not characterized\", \"Endogenous physiological substrate hierarchy unknown\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Mapping CBR1 to chromosome 21q22.12 and demonstrating gene-dosage-dependent elevation of mRNA and activity in trisomy 21 cells raised the possibility that CBR1 overexpression contributes to Down syndrome phenotypes.\",\n      \"evidence\": \"FISH mapping with enzyme activity and mRNA quantification in aneuploid lymphoblast lines\",\n      \"pmids\": [\"8432528\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific DS phenotypes attributable to CBR1 dosage not yet identified\", \"Gene dosage effect in tissues beyond lymphoblasts not assessed\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identification of the V88I functional polymorphism revealed that a single residue change alters Vmax, NADPH affinity, and inhibitor sensitivity, providing the first molecular explanation for inter-individual variation in CBR1-dependent drug metabolism.\",\n      \"evidence\": \"Recombinant enzyme kinetics and isothermal titration calorimetry for NADPH binding with both isoforms\",\n      \"pmids\": [\"17344335\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Population frequency and clinical penetrance of V88I not yet established\", \"Structural basis for altered cofactor affinity not resolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Discovery that AHR induces CBR1 transcription through two XRE elements, validated in Ahr-knockout mice, established the first transcriptional regulatory axis for CBR1 and linked xenobiotic sensing to carbonyl reductase capacity.\",\n      \"evidence\": \"Promoter-reporter deletion/mutation analysis, TCDD/β-naphthoflavone induction, and Ahr−/− mouse model\",\n      \"pmids\": [\"17569794\", \"22531821\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether AHR-CBR1 induction is protective or detrimental in chronic xenobiotic exposure not resolved\", \"Contribution of distal vs. proximal XRE in vivo unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Structure–function analysis of the CBR1 substrate-binding loop (residues 236–244) identified the molecular determinants that confer its dramatically higher catalytic efficiency compared to CBR3, explaining paralog specificity.\",\n      \"evidence\": \"Site-directed mutagenesis with chimeric CBR1/CBR3 constructs and enzyme kinetics for isatin and phenanthrenequinone\",\n      \"pmids\": [\"19061875\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full structural model of the substrate-binding pocket with bound substrate not available\", \"Whether these residues similarly govern anthracycline specificity not tested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"A pharmacogenetic study in childhood cancer survivors linked CBR3 V244M genotype—and to a lesser extent CBR1 1096G>A—to anthracycline cardiomyopathy risk, translating earlier enzymology into a clinically relevant pharmacogenomic marker.\",\n      \"evidence\": \"Case-control study in 487 childhood cancer survivors with conditional logistic regression\",\n      \"pmids\": [\"22124095\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"CBR1 genotype effect did not reach independent significance in this cohort\", \"Replication in prospective studies needed\", \"Mechanistic link between CBR1 genotype and cardiotoxic metabolite levels in patients not directly measured\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Nrf2 was established as a second transcriptional activator of CBR1, binding an ARE in the promoter, thereby connecting oxidative stress sensing to CBR1 induction and positioning CBR1 within the cellular antioxidant defense program.\",\n      \"evidence\": \"EMSA, luciferase reporter with ARE mutation, Nrf2 cotransfection, and BHA treatment in HepG2 cells\",\n      \"pmids\": [\"23247010\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of Nrf2 vs. AHR to basal CBR1 expression not quantified\", \"Nrf2-CBR1 axis not validated in vivo at this stage\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Cbr1 haploinsufficiency in a mouse tumor model demonstrated that CBR1 enzymatic conversion of doxorubicin limits its therapeutic efficacy in vivo, with unexpected sex-dependent expression differences explaining differential tumor responses.\",\n      \"evidence\": \"Cbr1+/− mice crossed with PyVT mammary tumor model; sex-specific Western blotting of Cbr1 in liver/kidney\",\n      \"pmids\": [\"22343424\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of sex-specific Cbr1 expression not elucidated\", \"Cardiotoxicity was not measured alongside efficacy\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"ChIP-validated glucocorticoid receptor binding at the CBR1 promoter, combined with functional knockdown and inhibitor experiments, identified GR as a third transcriptional regulator and established that cortisol-driven PGE2→PGF2α conversion in amnion is mediated by CBR1.\",\n      \"evidence\": \"ChIP for GR and RNA Pol II, siRNA knockdown of GR and CBR1, RU486 antagonism, PGF2α ELISA in primary human amnion fibroblasts\",\n      \"pmids\": [\"24654784\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Role of CBR1-mediated prostaglandin conversion in parturition timing not tested\", \"Whether GR directly or indirectly occupies the CBR1 promoter (cofactor requirements) not resolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Delivery of Tat-CBR1 into macrophages demonstrated that CBR1 enzymatic activity suppresses NF-κB and MAPK signaling, establishing CBR1 as an active anti-inflammatory effector rather than merely a passive metabolic enzyme.\",\n      \"evidence\": \"Tat-CBR1 protein transduction into RAW 264.7 macrophages with LPS stimulation; TPA ear edema model in mice\",\n      \"pmids\": [\"25818598\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether the anti-inflammatory effect requires catalytic activity or is mediated by protein–protein interaction not distinguished\", \"Endogenous substrate responsible for NF-κB suppression not identified\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identification of RACK1 as a physical interactor that stabilizes CBR1 protein connected CBR1 regulation to the RACK1 signaling scaffold and showed that RACK1-CBR1 axis controls ROS and cell survival.\",\n      \"evidence\": \"Co-immunoprecipitation, RACK1 siRNA, CBR1 overexpression rescue, ROS measurement in HCC cells\",\n      \"pmids\": [\"28105239\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Reciprocal Co-IP not reported\", \"Binding interface and stoichiometry unknown\", \"Whether RACK1 stabilizes CBR1 by blocking ubiquitination or other degradation pathways not determined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Genetic normalization of Cbr1 copy number in a Down syndrome mouse model demonstrated that CBR1 triplication reduces PGE2 and impairs spatial memory, directly linking CBR1 gene dosage to a specific DS cognitive phenotype through prostaglandin metabolism.\",\n      \"evidence\": \"Ts1Cje mice with Cbr1 copy-number normalization; hippocampal electrophysiology, behavioral testing, PGE2 measurement\",\n      \"pmids\": [\"32843708\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PGE2 supplementation alone rescues memory not tested\", \"Contribution of CBR1 to other DS phenotypes (cardiac, immune) not assessed\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"CBR1 inhibition by chrysin was shown to trigger ROS-dependent autophagic degradation of ferritin heavy chain, elevating free iron and inducing ferroptosis in pancreatic cancer cells, revealing a previously unknown role for CBR1 in ferroptosis suppression.\",\n      \"evidence\": \"Direct binding assay, enzymatic inhibition, ROS/ferroptosis markers, siRNA knockdown, and xenograft validation\",\n      \"pmids\": [\"34673014\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific CBR1 substrate whose reduction prevents ROS accumulation not identified\", \"Whether ferroptosis induction generalizes to other cancer types not established\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"CBR1 overexpression was found to promote cancer stemness and quiescence via SETD4, and CBR1 inhibition disrupted this program to sensitize NSCLC cells to cisplatin, positioning CBR1 as a druggable node linking metabolic activity to stem-cell-like drug resistance.\",\n      \"evidence\": \"shRNA/pharmacological CBR1 inhibition, SETD4 rescue, flow cytometry for G0, xenograft model\",\n      \"pmids\": [\"41490728\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How CBR1 enzymatic activity regulates SETD4 expression is mechanistically undefined\", \"Whether this axis operates in non-NSCLC cancers not tested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Post-transcriptional regulation of CBR1 was established via IGF2BP2/m6A-dependent mRNA stabilization and E2F2→miR-1290-mediated suppression, expanding the regulatory landscape of CBR1 beyond transcriptional control.\",\n      \"evidence\": \"IGF2BP2 knockdown with mRNA stability assay and CBR1 rescue in colitis model; ChIP and dual-luciferase for E2F2/miR-1290/CBR1 axis in PSD rat model\",\n      \"pmids\": [\"40526983\", \"41310140\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether m6A modification and miR-1290 regulation operate in the same tissues/contexts not known\", \"Specific m6A site(s) on CBR1 mRNA not mapped\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Nrf2-CBR1 axis was independently validated in osteoblasts as protective against PGE2-induced ferroptosis via vitamin K2-mediated Nrf2 stabilization, confirming the Nrf2-CBR1 regulatory connection in a non-cancer, non-liver context.\",\n      \"evidence\": \"EMSA, ChIP-qPCR for Nrf2 at CBR1 promoter, Keap1 ubiquitination assay, in vivo osteoporosis model\",\n      \"pmids\": [\"40721947\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether CBR1 directly metabolizes PGE2 to reduce ferroptosis or acts through ROS clearance not distinguished\", \"Relative contribution of CBR1 vs. other Nrf2 target genes to ferroptosis protection unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The endogenous substrate hierarchy of CBR1 in different tissues remains undefined, and the mechanism by which CBR1 enzymatic activity controls SETD4-dependent stemness signaling and NF-κB/MAPK suppression has not been resolved at the metabolite level.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No metabolomics-based identification of the dominant endogenous CBR1 substrate in vivo\", \"Structural basis for isoform-specific inhibitor sensitivity (V88 vs I88) not crystallographically resolved\", \"Whether CBR1 anti-inflammatory and ferroptosis-protective roles converge on the same substrate or represent distinct activities is unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [0, 2, 4, 5, 12, 16, 18, 19, 23]},\n      {\"term_id\": \"GO:0016209\", \"supporting_discovery_ids\": [0, 13, 18]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 16]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-9748784\", \"supporting_discovery_ids\": [0, 2, 6, 8, 16, 23]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 10, 17]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [21, 22]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [3, 7, 9, 13, 18, 24]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [18, 24]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [11, 21]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"RACK1\",\n      \"NRF2\",\n      \"AHR\",\n      \"GR\",\n      \"IGF2BP2\",\n      \"SETD4\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}